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Qian Zhang, Doctor of Philosophy 
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Major Professor: Cheng-Wei Tom Chang 
Department: Chemistry and Biochemistry 
This dissertationis composed of two research projects. The first 
research project is aimed at using synthetic fluorogenic probes to study the 
possible or dominant linkages in biomass. These probes that mimic the 
linkages found in lignin-cellulosic biomass are designed to select the optimal 
fungi from direct evaluation process or could be tested against other 
microbials to screen candidates which can break ligno-hemicellulose bonds. 
For the first stage, these probes would be tested against white rot fungi 
extract. The white rot fungi are used for the first stage to see if releasing or 
degrading carbohydrates while keeping lignin largely intact is possible or not. 
These probes can help to answer fundamental questions, such as what 
could be the dominant linkages between lignin and hemicellulose, and what 
are the possible mechanisms for the cleavage of carbohydrates in biomasses. 






degradation or release of carbohydrates, primarily hemicelluloses, from 
biomass.  
The second project is focused on synthesizing new aminoglycoside 
analogs and exploring the potential to revive traditional antibacterial 
kanamycin as new types of antifungal agents. Aminoglycosides are widely 
used broad spectrum antibiotics. Although mainly used as antibacterial 
agents, there have been studies to show amphiphilic aminoglycoside 
derivatives could be possibly employed as antifungal agents.  
A concise and novel method for site-selective alkylation of tetra-
azidokanamycin has been developed that leads to the divergent synthesis of 
three classes of kanamycin derivatives. These new amphiphilic kanamycin 
derivatives bearing alkyl chains length of 4, 6, 7, 8, 9, 10, 12, 14，16 have 
been synthesized and tested against bacteria and fungi. Surprisingly, the 
antibacterial effect of the synthesized kanamycin derivatives decline or 
disappear compared with the original kanamycin A, but some of the 
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         For the first project, a library of fifteen commercially purchased and 
synthetic fluorogenic probes were employed for the investigation of biomass 
degradation using extract of white-rot fungi. These discoveries prove that it is 
possible to employ fungi for selective degradation or release of hemicelluloses 
from biomass. This work is supported by Sun Grant Western Regional 
Center/DOT “Bioprospecting for Enzymes to Break Lignin-Hemicellulose 
Bond” ($300,000,09/01/2011-08/31/2013) 
The second project is focused on synthesizing new aminoglycoside 
analogs and exploring the potential to revive traditional antibacterial 
kanamycin as new type of antifungal agents. Although aminoglycosides 
antibiotics are mainly used as antibacterial agents, this project prove that it is 
possible to convert kanamycin to amphiphilic antifungal agents through simple 
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1-1. Overview of Project 1：Biomass, a Promising Source of Renewable Energy 
1-1.1．Rationale for the Planned Work 
Nowadays, the United States imports large amounts of petroleum to help 
satisfy energy and chemical needs.1 Alternatively, both fuels and chemicals can 
be generated from biomass in bio-refineries. Corn starch was used as feedstock 
for the first generation bio-refineries. Unfortunately, cultivating agricultural crops 
as a source of biomass is energy intensive and escalates competition between 
the use of land for food or for fuel.2 Thus, second and third generation bio-
refineries have focused on ligno-cellulosic sources of biomass including 
agricultural waste, energy crops such as switchgrass, and wood waste.  
At the same time, with the increasing price of fossil fuel and the serious problem 
of global warming, discovery of sustainable and renewable energy and reduction 
of fossil fuel consumption are the imminent challenge for mankind to ensure 
continuing prosperity. Many national government agencies, including NSF and 
DOE, have missions and emphasis on the development of technologies to 
produce energy (or alternative energy) from wind, solar, biomass, and 
geothermal sources.3 While there are many reasons to embrace alternative 
energy, common problems like cost and reliability, are often associated with each 
form and, thus, hinder the application of these technologies.4-5 For instance, 




are common.6Biomass is a very promising renewable energy source, bio-energy 
has been now accepted as major part of the projected renewable energy 
provisions of the future as biofuels in the form of gas, liquid or solid fuels or 
electricity and heat.7The most widely used method to obtain biofuels is to ferment 
the sugar components from starch crops to produce ethanol, which can be used 
as gasoline (the 1st generation of biofuel production).8-10 
 We believe that non-edible biomass is a superior source for alternative 
energy in the category of biofuel form which is known as the 2nd generation of 
biofuels. Unlike solar or wind energy, the supply of feedstock biomass is 
immense and low cost. For many years, the main issues of utilizing non-edible 
biomass is the difficulties in developing a low-cost and continuous separation 
methods for extracting fermentable carbohydrates (cellulose or hemicellulose) 
from the biomass.11 
 Transformation of biomass into energy, commonly in the form of ethanol, 
has been intensively studied. And procedures for industrial scale production has 
already been established.12-18 Cellulose, lignin and hemicellulose are the three 
major biomaterials in biomass. Despite decades of intensive investigations, 
progress on utilizing cellulose in biomass as the energy source is still not 
satisfactory. Cellulose contains sturdy and complex structures, which make it 
difficult to be broken down using chemical, mechanical or biological methods. 
The similar problem also presents in degradation of lignin. Therefore, there is a 






ethanol production. The common practices for removing hemicellulose from 
biomass, especially those employed by paper-making industry during the wood 
pulping, involve the uses of caustic chemicals (acids, alkaline, ammonia, ozone) 
and/or harsh mechanical conditions (pyrolysis, steam explosion).19-21 These 
practices have the disadvantages of producing chemical wastes that requires 
further treatments or immense energy investment during the operations. As a 
result, there is an ongoing effort in searching for "green" process for 
hemicellulose isolation, and microbes for cost-effective biofuel production.10 
 Due to the capability of fast rotting of wood, fungi have been the focus for 
biodegradation of biomass. This process can be free of hazardous chemicals and 
requires little energy investment.8,22 Extensive investigations have been devoted 
into the search for fungi, the studies of fungal enzymes and the genetic 
modification of microbes.24 However, little progress has been noted. The major 
challenges are the complexity of enzymes employed by various fungi: not all the 
targeted fungi can degrade wood in a satisfactory efficiency. To make matters 
worse, the composition of enzymes may change upon alteration of growing 
environments and factors, such as, temperature, humidity and nutrition. 
Consequently, inconsistency in the outcomes was often observed. Additionally, a 
main obstacle is that the degradation of lignin will generate phenols or quinones, 
which are toxic to the microbes (commonly yeasts) that will be used for the 
fermentation of carbohydrates produced from biomass. Over degradation of 
lignin will also lead to the formation of excess tar during the gasification of 






phenols or quinones which further complicate the process of ethanol or biofuel 
production. All of the above-mentioned problems make the biofuel production 
from hemicellulose or cellulose using biomass not effective in cost and energy-
consumption. In summary, an ideal method for converting ligno-cellulosic 
biomass that can be used as the substitutes of fossil fuel and coal has not been 
completely developed, yet. Thus, we believe that understanding the linkages in 
biomass is pivotal in developing a practical method of utilizing carbohydrates in 
biomass. 
          White rot fungi have long been investigated for their capability to break 
down the biomass in wood. Among the many species, Phanerochaete 
chrysosporium (ATCC24725) has been studied by Prof. Steve Aust in the 
Department of Chemistry and Biochemistry for many years at Utah State 
University. White rot fungi use cellulases and peroxidases to degrade cellulose, 
lignin and hemicellulose.29-30 However, there is no selectivity observed between 
cellulose/hemicellulose and lignin. This is common among most of the wood 
decaying fungi.25 
The dominant structures of cellulose, hemicellulose and lignin are shown in 
Figure 1-1. Cellulose contains polysaccharide chains predominately consisting of 
glucose in β-1,4 linkages (Figure 1-a). There are two major types of 
hemicellulose: xylan and mannan (Figure 1-b).31 Xylan has polysaccharide 
chains consisting of β-1,4 linked xylose. The polysaccharide chains are 






consisting β-1,4 linked mannose as the major repeating unit and little α-1,6 linked 
mannose. It has been proposed that hemi-celluloses are covalently linked to 
lignin via ether or alkyl types of linkages. However, the details of these linkages 
have not been fully revealed. Lignin is a rather complex biopolymer that contains 









































R = CH2OH orCO2
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b) Representative Structure of Hemicellulose

























































1-1.2. Aims and Objectives 
          The proposed research is aimed at using synthetic fluorogenic probes to 
study the possible or dominant linkages in biomass. These probes that mimic the 
linkage found in lingo-cellulosic biomass are designed to select the optimal fungi 
from direct evaluation process. The selected fungi are expected to release or 
degrade carbohydrates while keeping lignin largely intact. 
         These probes can help to answer the fundamental questions, such as what 
could be the dominant linkages between lignin and hemicellulose, and what are 
the possible mechanisms for the cleavage ofcarbohydrates in biomass. 
Understanding the linkages in this source of biomass will enable highly efficient 
degradation or release of carbohydrates, primarily hemicelluloses, from biomass. 
The resulting carbohydrates can be used for biofuel production via fermentation, 
or thermochemical or thermo-catalytic conversions. The successful manipulation 
and selection of new fungi will help to address the problems of biofuel production 
from biomass, and consequently problems associated with alternative energy 
production from other sources. Overall, it may allow a convenient and 
economical utilization of these carbohydrates as the feedstock for biofuel 










1-2. Overview of Project 2: Traditional Aminoglycosides and Their New 
Application 
1-2.1. Introduction to Aminoglycosides 
Aminoglycoside antibiotics are one of the most important broad spectrum 
antimicrobials that have been used in clinic for more than 60 years. Even though 
aminoglycosides have a problem of potential nephrotoxicity and ototoxicity, they 
remains valuable and sometimes play an irreplaceable role for the treatment of 
infectious diseases.34Streptomycin (Figure 1-2) was discovered as the first anti-
tuberculosis agent in 1944 from the bacterial culture supernatants.35Since then, 
more and more aminoglycosides were isolated from nature including kanamycin, 
gentamicin, and tobramycin, which were used to treat bacterial infectious 











         Naturally occurring aminoglycosides are produced by Streptomyces and 
Micromonospora soil bacteria,36 which proactively methylate their ribosomes to 
survive the bactericidal action of their secondary metabolites.37Among the 
commonly used aminoglycoside antibiotics, the kanamycin class(Figure 1-3) 
show prominent antibacterial activity for both Gram-positive and Gram-negative 
bacterial. Nevertheless, the prevalence of aminoglycosides-resistant bacteria has 
significantly reduced the effectiveness of kanamycin. In order to solve the 
problem of drug resistance, chemical modification of kanamycin is the most 
popular and effective method to revive its activity against resistant bacterial.38-
39The discovery of amphiphilic aminoglycosides that can exert unexpected 
antimicrobial activities has led to a new strategy of broadening the applications of 





























Kanamycin A        OH   OH    OH   H
Kanamycin B        OH   NH2   OH   H
Dibekacin              NH2  H       H     H
Tobramycin           NH2  H      OH   H
Amikacin               OH    OH   OH   AHB
Arbekacin              NH2  H       H     AHB
    AHB: (S)-4-amino-2-hydroxybutyryl










1-2.2. Investigation of Antibacterial to Antifungal Conversion of Kanamycin  
Compared to the investment in the development of antibacterial, antiviral and 
anti-cancer therapeutics, antifungal drug discovery is relatively neglected in 
medical research. Pathogenic fungi, such as Aspergillis fumigatus, Candida 
albicans, Cryptococcus neoformans, and Histoplasma capsulatum pose serious 
threats to human health.43 Only a few new fungicides have been introduced since 
the mid-1980s.44 Resistance to existing antifungal drugs is another serious 
challenge. Many fungicides used in agriculture are heterocyclic compounds 
which are chemically synthesized, such as triazoles and pyrimidines.These 
heterocyclic compounds highly resemble the antifungal drugs used for treatment 
of fungus infections in humans. As a result, resistant fungi found in agriculture 
and the environment have counterparts that have evolved among pathogenic 
fungi found in humans.45 Thus, there is an urgent need for the development of 
novel fungicides.  
Our group has previously reported the synthesis and antifungal investigation of 
a novel broad-spectrum fungicide FG08 and K20 (Figure 1-4).46,47 Plant leaf 
infection assays and greenhouse studies showed that FG08 is capable of 
suppressing wheat fungal infections by Fusarium graminearum which is the 
causative agent of Fusarium Head Blight. FG08 can be viewed as a kanamycin B 
derivative with three distinct structural modifications, all on ring III: a linear octyl 
group at O-4" position, deoxygenation at O-6" position and the replacement of 






group is essential for converting the antibacterial kanamycin into an antifungal 
agent. Further investigations have confirmed that FG08 exerts its antifungal 
activity by specifically disrupting the fungal plasma membrane, a mechanism of 
action that differs from the antibacterial action of kanamycin of binding ribosomal 






































Figure 1-4: Structure of FG08 and K20 
 
To elucidate the structure activity relationship (SAR) for this phenomenon, a 
library of kanamycin analogs, alkylated with several different chain lengths and at 
various hydroxyl groups of kanamycin were synthesized (Figure 1-5).48The 
synthesized kanamycin B analogs were again tested for growth inhibitory 
activities against the filamentous fungus F. graminearum, the G- bacterium E. 
coli (ATCC25922) and the G+ bacterium S. aureus (ATCC25923, G+) (Table 1-1 






























FG05, R = C6H13














































































FG10, R = OH



























FG12, R = C8H17, R' = OH





























FG08, R = C8H17
FG01, R = C4H9




















































FG14, R1 = C8H17, R2 = H, R3 = H 
FG15, R1 = H, R2 = C8H17, R3 = H
FG16, R1 = H, R2 = H, R3 = C8H17
FG17, R1 = H, R2 = C8H17, R3 = C8H17 
















Entry Alkylation site Compound 
MIC (µg/mL) 
Butte 86  B4-5A 
1 O-4’’(C4H9) FG01 250 250 
2 O-4’’(C12H23) FG02 125 250 
3 O-4’’(C8H17) FG08 31.3 15.6 
4 - kanamycin >500 250 
 




















Entry Alkylation site Compound 
MIC (µg/mL) 
F. graminearum  E. coli S. aureus 
1 O-2'' FG09 20 ≥250 ≥250 
2 O-3'' FG07 62.5 125-250 64-125 
3 O-4'' FG03 (6''-OH) 7.8 ND ND 
4 O-4'' FG08 (6''-H) 7.8 64 32-64 
5 O-6'' (C6H13) FG05  125 ≥250 ≥250 
6 O-6'' (C8H17) FG06  31.3 ≥250 ≥250 
7 O-5 FG10 (3''-OH) ≥500 ≥250 ≥250 
8 O-5 FG11 (3''-NH2) 31.3 32-64 64-125 
9 O-3' & O-4' FG12&FG13 ≥500 ≥250 ≥250 
10 O-2'' FG14 62.5 125-250 125-250 
11 O-4'' FG15 15.6 125 125 
12 O-6'' FG16 31.3 64-125 125 
13 O-4" and O-6" FG17 31.3 125 32 
14 O-2" and O-4" FG18 31.3 125 32 
15 - kanamycin ≥500 4 1 
 








From our study, we have shown that O-4" position is the optimal site for attaching 
a linear alkyl chain that will enable the conversion of antibacterial kanamycin into 
an antifungal agent (Table 1-2, Entry 3, 4 and 11). Octylation at the hydroxyl 
groups on ring I or II causes the loss of antibacterial activity and no gain in 
antifungal activity. We have showed that the 3"-NH2 group has no or even 
negative role in generating antifungal activity. We have also revealed that the 
structure of the core molecule and the site where the linear alkyl chain is 
essential for the selective antifungal activity. The fact that FG03 has the same 
level of antifungal activity as FG08 indicates deoxygenation at 6"-OH is not 
necessary. These findings provides a more accessible synthetic route for scale 
up production of future lead compound(s). There is a growing interest in the 
antibacterial activities of amphiphilic aminoglycosides. Our work here not only 
offers a new application of amphiphilic aminoglycosides, but also details in the 
structure activity relationship that will maximize the antifungal activity. These 
SAR investigations could possibly lead to the development of new antifungal 











1-2.3. Research Summary for Previous Work 
FG compounds show very promising potential for becoming antifungal 
amphiphilic aminoglycosides. Unfortunately,the syntheses of these FG 
compounds usually involves multistep chemistry including protection/de-
protection strategies and glycosylation reactions that limit the synthesis and 
application of the FG compounds. The quantity of final FG compounds we can 
make is usually around 0.1 g. Allthe FG compounds from our library are 
derivatives of kanamycin B, which is not naturally abundant among kanamycin 
family. On the other hand, kanamycin A is much more economical and 
accessible in large quantity compared to kanamycin B, however it has not been 
investigated a lot for its potential to become new type of antifungal agent.  So the 
aim of the follow up research is to perform chemical modification of kanamycin A 
to answer the following questions: 
1. Will kanamycin A show antifungal property after being chemical modified 
to amphiphilic type of aminoglycosides? 
2. Is there a simplified synthetic strategy which could reduce the synthetic 
steps and improve the yield of the modified aminoglycosides?  
3. How will the alkyl chain length affect the antifungal activity and is 8 carbon 
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USING FLUOROGENIC PROBES FOR THE INVESTIGATION OF SELECTIVE 
BIOMASS DEGRADATION BY FUNGI1 
2-1.Abstract 
Alibraryoffifteen commercially purchased and synthetic fluorogenic probes was 
employed for the investigationof biomass degradation using extracts of white-rot 
fungi. These probes were selected or designedto mimic the dominant linkages in 
celluloses, hemicelluloses, and lignin, the three most abundant polymersfound in 
biomass. The results show that white-rot fungi display a high preference for 
cleavingmannose- and glucose-based probes, which mimic hemicelluloses. Low 
degrees of cleavages werenoted for xylose- and cellobiose-based probes. No 
cleavages were observed for probes that mimic thelinkages in lignin. Overall, 
these discoveries prove that it is possible to employ fungi for selective 




1Adapted with permission from [Qian Zhang, Xinrui Peng, Michelle Grilley, Jon Takemoto, Cheng-









Celluloses, hemicelluloses (commonly present in forms, such as xylan, 
arabinoxylan, mannan and glucomannan) and lignin are the three most abundant 
polymers found in biomass. Non-edible biomass is a superior source for 
alternative energy in the category of 2nd generation biofuels. Unlike solar or wind 
energy, the supply of feedstock biomass is immense and low cost. Using fungi 
for biodegradation of biomass and release of carbohydrates is an effective and 
environmentally friendly way of providing feedstock for biofuel production. 
However, for many yearsthe main issue for utilizing non-edible biomass has been 
the difficulties in developing low-cost and continuous separation methods for 
extracting fermentable carbohydrates (cellulose or hemicellulose) from the 
biomass.1 The common practices for removing hemicellulose from biomass, 
especially those employed by the paper-making industry during wood pulping, 
involve the uses of caustic chemicals (acids, alkaline, ammonia, ozone) and/or 
harsh mechanical conditions (pyrolysis, steam explosion).2 These practices have 
the shortcoming of producing chemical wastes that require further treatments or 
immense energy investments. As a result, there is an ongoing effort in searching 
for "green" processes for hemicellulose isolation, and microbes for cost-effective 
cellulose-based biofuel production.3 
Due to the capability of fast rotting of wood, fungi have been the focus for 
biodegradation of biomass. This process can be free of hazardous chemicals and 
requires little energy investment.3a,4 Extensive investigations have been devoted 
to the search for fungi, studies of fungal enzymes and the genetic modification 






are the complexity of enzymes employed by various fungi: not all the targeted 
fungi can degrade wood with satisfactory efficiency. Another obstacle is that the 
degradation of lignin will generate phenols or quinones, which are toxic to the 
microbes, commonly yeasts, that will be used for the fermentation of the 
carbohydrates produced from biomass.5 Over degradation of lignin will also lead 
to the formation of excess tar during the gasification of biomass.6 Therefore, 
chemical treatments are required to remove these phenols or quinones which 
further complicates the process of ethanol or biofuel production. We believe that 
an ideal solution is to identify strains of fungi that can selectively degrade or 
release hemicellulose from biomass without significant degradation of lignin.  
Hemicelluloses are thought to link to lignin via covalent bonds. Although the 
exact linkages have not been fully characterized, they most likely involve in the 
form of glycosidic bond to anomeric carbon or to hydroxyl groups in the form of 
ether bond (Figure 2-1).7 For achieving the goal of selective degradation or 
releasinghemicellulose, a library of synthetic and commercially available 
fluorogenic probes were screened to show their usefulness in identifying and 
characterizing such linkages. These probes were designed to contain linkages 
that mimic those found in biomass, including: 
A. The first type (class I) with a chromophore attached to the anomeric position 
of cellobiose to mimic cellulose; 
B. The second type with chromophores attached to the anomeric positions of 
xylose, mannose, and glucose (class IIa) to mimic the anomeric linkages 






hydroxy groups of mannopyranose and xylofuranose to mimic the ether 
linkages between hemicelluloses and lignin (class IIb);  

















glycosidic bond  
 









2-3. Design and Synthesis of Fluorogenic Probes which Mimic Lignin-






            Two types of chromophores were employed. 4-Methylumbelliferone 
(4MU), 1 will be used in the designs that mimic the phenolic link. 6-
methoxynaphthalenecarbonyl (6MN) motif, 2 was used in the designs that mimic 
linkages between hemicellulose and lignin at phenolic and benzylic positions 
(Figure 2-2). These molecules show no fluorescence when linked to 
carbohydrates or other structural moieties. However, upon degradation or 
breaking of the designed chemical bonds, fluorescent molecules are released, 
and are thus termed fluorogenic. In addition, 4MU undergoes hydrolytic cleavage 
whereas 6MN fluorescence only occurs after oxidative cleavage. Thus, these two 
probes can also differentiate the possible mechanismsinvolved in the breakage 



















































































































































All the probes used with 4MU at the anomeric position are commercially 
available. The synthesis of probe 17 began with converting the per-acetylated 
cellobiose into the glycosyl bromide followed by glycosylation using (6-methoxy-
2-naphthyl)methanol, 7 as the glycosyl acceptor. Deacetylation of 6 afforded the 
desired probe 17. Similar processes were used for the syntheses of probes 14 
and 16 (Scheme 2-1). 
 
1) HBr/HOAc
2) 7, Ag2CO3 




















































2) 7, Ag2CO3 
    4A MS, CH2Cl2
1) HBr/HOAc
2) 7, Ag2CO3 



























Probe 1 was synthesized with alkylation of methyl 2,3,4,-tri-O-benzoyl-α-D-
mannoside, 11 using a 6MN derivative, (6-methoxynaphthalen-2-yl)methyl-2,2,2-
trichloroacetimidate, 12 followed by the removal of the benzoyl groups (Scheme 
2-2). Probe 3 was prepared from methyl mannopyranoside, 14 via a Mitsunobu 

















































Similar to the synthesis of probe 3, probe 4 was prepared from 1,2-O-
isopropylidene-α-D-xylofuranose via aMitsunobu reaction followed by the 
removal of the isopropylidene group (Scheme 2-3). In a separate route, the 3-OH 
of compound 15 was alkylated with 6MN. Following the removal of both trityl and 
isopropylidene groups, probe 5is isolated which could exist as an equilibrium of 








   72%
HOAc:H2O:TFA = 80:20:1






































Scheme 2-3: Synthesis of Probe 4 and Probe 5 
 
Probe 10 can be synthesized by alkylation of the hydroxyl group of 17 with 19 
(Scheme 2-4). Probe 11 can be prepared by bromination of the α-carbon of 20 






wassynthesized viaa Mitsunobu reaction, and it has also been synthesized and 






































21 Probe 12  
 











2-4. Results and Discussion 
White rot fungus, Phanerochaete chrysosporium (ATCC24725), which uses 
cellulases and peroxidases to degrade cellulose, lignin and hemicellulose, has 
been studied for many years.4d,8 All the probes were tested using crude extract of 
P. chrysosporium. The fluorescence intensities of the inoculated solutions were 
observed every ten minutes using excitation at 360 nm and emission at 460 nm, 
and the data was collected up to five and half hours. Relative fluorescence 
intensity (RFI) values were calculated as the difference in fluorescence intensity 
between the inoculated solutions and controls (no crude extract of P. 
chrysosporium added). The RFI value for each probes was determined 6-9 times 




































III.2 Discussion and Conclusion 
       The data show that only two of the class IIa probes (probes 7 and 8) 
displayed a significant fluorescence increase, showing a time-dependent 
increase in RFI. Probe 9 also manifested a time-dependent but rather small 
increase in RFI. All three probes have 4MU attached at the anomeric position, 
whereas similar probes with 6MN attached at the anomeric position (probes 14 
and 16) showed no obvious fluorescence increase. Since 6MN can be 
fluorescent only via oxidative cleavage, this result suggests that the activity of 
glycosidases and not peroxidases are responsible for the degradation. However, 
it is worth mentioning that the lack of fluorescence from probes 14 and 16 cannot 
be considered as the lack of fungal enzyme activity. In fact, we believe that 
fungal glycosidases can degrade these two probes. Nevertheless, the possible 
adducts 6-methoxy-2-naphthlenemethanol from such degradation were not 

























         The lack of fluorescence increase from class IIb probes attached with either 
4MU or 6MN also implies that peroxidases or etherases cannot degrade xylose- 
or mannose-based hemicelluloses, which are connected to lignin via ether 
linkages. Therefore, it is possible to release or degrade glucose, xylose or 
mannose-based hemicelluloses only when these are connected to lignin via 
glycosidic bonds.  
         The lack of fluorescence increase from class III probes and very little 
fluorescence increase from class I probes supports the idea of using fungi to 
selectively degrade or release hemicelluloses without breaking down celluloses 
or lignin from biomass. To confirm that the aromatic compounds generated from 
the degradation of class III probes (probes 10, 11, and12) will not cause 
fluorescence quenching, we have measured the fluorescence of pre-mixed 
aromatic compounds and 4MU. Three aromatic adducts from the possible 
degradation of class III probes were used for this investigation: 3,4-
dimethoxyacetopheone (A), 3,4-dimethoxybenzyl alcohol (B) and 2-(3,4-
dimethoxylphenol)-ethanol (C). The fluorescence measure showed no quenching 
of 4MU from these aromatic compounds. There was only a slight decrease in 
fluorescence when 4MU was mixed with 3,4-dimethoxyacetopheone and no 
changes on the other two combinations. The results confirm that no fluorescence 








Figure 2-9: Incubation of 4MU with Aromatic Compounds 
 
Nevertheless, there is a slight and time-dependent fluorescence increase for 
probe 18. It is possible that celluloses may still be degraded but at a much slower 
rate than that of the hemicelluloses. In contrast to probe 8 (mannose with β-
linked 4MU), probe 19 (mannose with α-linked 4MU) did not exhibit an increase 
in RFI. Plant mannans are mannose-based polysaccharides with mannose linked 
with β(1–4) linkages while yeasts and mammalian glycoproteins have mannose-
based oligosaccharides carrying mannose linked with α(1–6) as the backbone, 






probe 19 strongly indicates that the fungal enzymatic degradation is very 
selective toward the plant mannans. 
             Finally, based on the time-dependent but small increase in RFI of probe 
18, the possibility that the rate of enzymatic degradation/release on 
hemicelluloses may be slower for polymers consisting of xylose, mannose or 
glucose cannot be ruled out. It is difficult to design or envision a fluorogenic 
probe that can mimic the glycosidic bond between two carbohydrate units. 
However, since the cellobiose-based probe (probe 18) and, likely, probe 17 were 
degraded by the fungal enzymes, it is possible that the glycosidic bonds between 
xylose, mannose, or glucose-containing hemicelluloses and lignin can also be 
broken by fungal enzymes albeit, probably, at a slower rate when compared to 

















2-6. Experimental Section 
        Proton magnetic resonance spectra were recorded using JEOL ECX-
300, or Bruker ARX-400 spectrometer. Chemical shifts were reported as parts 
per million (ppm) downfield from tetramethylsilane in δ unit and coupling 
constants were given in cycles per second (Hz), Signal multiplicities were 
indicated by s (singlet), d (doublet), t (triplet), and q (quartet), m (multiplet). 13C 
NMR spectra were obtained using JEOL ECX-300 at 75 MHz, or Bruker ARX-
400 at 100 MHz. Routine 13C NMR spectra were fully decoupled by broad-broad 
WALTZ decoupling. All NMR spectra were recorded at ambient temperature. 
Low-resolution fast-atom bombardment (LRFAB), high-resolution fast-atom 
bombardment (HRFAB), high-resolution MALDI, chemical ionization (CI), 
atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI) 
were provided by the Mass Spectrometry Facility, University of California, 
Riverside.  
        Chemical reagents and chromatography solvents were purchased from 
Aldrich Chemical Co. or Acros Chemcial Co. and were used without purification 
unless otherwise noted.  Dichloromethane was freshly distilled from calcium 
hydride under nitrogen atmosphere. Pyridine and triethylamine were distilled and 
stored over 4Å molecular sieve. Column chromatographic purifications were 
carried out on silica gel 230x450 mesh, Sorbent Tech. Analytical TLC was 
performed on Sorbent Technologies silica gel glass TLC plates. Visualization 






treating with diluted sulfuric acid (5% in methanol) solution or treating in iodine 
chamber, TLC staining for compounds bearing amine were done by treating with 
ninhydrin (in ethanol) and heating. 
           General procedure for assay of fluorogenic probes.10White rot 
basidiomycete, Phanerochaete chrysosporium, ATCC24725 was grown on 
potato dextrose agar (PDA) plates and incubated around 30°C for one week 
before the fungus was transferred to the liquid culture media. The culture 
medium contained, per liter: 2 g KH2PO4 (40 × stock), 0.5 g MgSO4•7H2O (40 × 
stock), 0.1 g CaCl2•2H2O (40 × stock), 1% glucose (10 × stock), 10 mM pH 4.2 
2,2-dimethyl succinate (10 × stock), 1 mg thiamin-HCl (1000 × stock), 0.2 g 
ammonium tartrate (40 × stock), and 10 mL of trace element solution (see 
below). The thiamin and KH2PO4 stock solutions are filter sterilized; the others 
are autoclaved as separate solutions. The stock solution of trace elements is 
made by first dissolving 1.5 g of nitrilotriacetic acid in 800 mL water and the pH of 
the solution was adjusted to approximately 6.5 with KOH. The following were 
then added with dissolution: 0.5 g MnSO4·H2O, 1.0 g NaCl, 0.1 g FeSO4·7H2O, 
0.1 g CoSO4, 0.1 g ZnSO4·7H2O, 10 mg CuSO4·5H2O, 10 mg AlK(SO4)2·12H2O, 
10 mg H3BO3, and 10 mg Na2MoO4·2H2O. Sterile distilled water was added to 
make the total volume of one liter. The medium was inoculated with a 100 mL 
suspension of fungal culture containing spores (absorbance of 0.5 at 650 nm).  
             For fungal growth, 10 mL portions of liquid cultures in the growth medium 






39°C. Enzyme production was stimulated by including 0.4 mM veratryl alcohol 
final concentration and trace elements (7 times the above concentration) at the 
time of inoculation. After one week growth, the 10 mL culture aliquots were 
centrifuged at 1500 RPM, 5°C for 15 minutes, and the supernatant was collected 
and directly used for enzymatic assays. In a 96 well microtiter plate, each well 
contained 100 uL 125 mM sodium tartrate (pH 3), 50 uL 10 mM probes, 50 uL 2 
mM H2O2, 50 uL culture supernatant. For the control, each well contains 100 uL 
125 mM sodium tartrate (pH 3), 50 uL 10 mM probes, 50 uL 2 mM H2O2 (freshly 
prepared), 50 uL H2O. Fluorescence was measured by using excitation 
wavelength at 360/40 and emission wavelength 460/40 at 37°C (40 stands for 
the filter band width). Two duplicated experiments were conducted in parallel. 
Each probes was assayed at least 6-9 times. 
            General procedure for the Mitsunobu reaction using primary alcohol 
and 4-methylumbelliferone (probe 3 and 16). To a solution of starting material 
(0.5 g) and 4-methylumbelliferone (1 equiv.) in 20 mL of anhydrous THF, 
triphenylphosphine (1.5 equiv.) and DIAD (1.5 equiv.) was added. The reaction 
was heated at 50 °C overnight. After completion of the reaction (confirmed by 
TLC, eluted withEtOAc), the solvent was removed and the product was purified 
by column chromatography (hexane/EtOAc from 80/20 to 0/100). The obtained 
product was further purified with recrystallization in a mixture of EtOAc/MeOH. 
            General Procedure for the Methanolysis of Acetyl Groups by NaOMe 
in MeOH. To a solution of acetylated sugars (0.1 g) in anhydrous MeOH (10 mL), 






stirred at room temperature for 6 hours. After completion of the reaction 
(confirmed by TLC, eluted with EtOAc/MeOH = 9/1), the reaction was quenched 
by adding Amberlite 120 (H+) resin. The reaction mixture was filtered through a 
short column packed with Celite, and the filtrate was collected and concentrated. 
The product usually would be in good quality but can be purified by a gradient 
column chromatography (eluted with CH2Cl2/MeOH from 100/0 to 4/1). The yields 
for deacetylation were usually between 90 – 100%. 
          Methyl-6-O-(6-Methoxy-2-naphthalenylmethyl)-mannopyronoside 
(probe 1). 1H NMR (300 MHz, METHANOL-D4) δ 7.7 (m, 3H), 7.43 (dd, J = 9.42, 
1.74 Hz,1H ), 7.19 (d, J = 2.43 Hz, 1H), 7.1 (dd, J = 8.91, 2.73 Hz), 4.7 (s, 3H), 
4.62 (d, J = 1.74, 1H, H1), 3.87 (s, 3H), 3.81 (t, J =10.32 Hz, 1H), 3.63-3.76 (m, 
5H), 3.36 (s, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 158.3, 134.7, 133.7, 
129.3, 129.2, 127.1, 126.7, 126.6, 118.8, 105.7, 101.8, 73.6, 72.4, 71.6, 71.0, 
70.1, 67.7, 54.7, 54.3; ESI/APCI calcd for C19H24O7+ ([M]+) 364.1522; measured 
364.1499. 
          Methyl-6-(4-methyl-umbelliferyl)-O-α-D-mannopyranoside (probe 3). 
1H NMR (300 MHz, METHANOL-D4) δ 7.66 (d, J = 8.94Hz, 1H), 7.0 (dd, J = 
8.94, 2.4 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.14 (d, J = 1.02 Hz, 1H), 4.63 (d, J = 
1.38 Hz, 1 H), 4.37 (dd, J = 10.65, 1.71 Hz, 1H), 4.26 (dd, J = 10.65, 5.85 Hz, 
1H), 3.8 (m, 2H), 3.73 (t, J = 8.91 Hz, 1 H), 3.69 (m, 1H), 3.36 (s, 3H), 2.42 (d, J 
= 1.35Hz, 3H). 13C NMR (100 MHz, METHANOL-D4) δ 162.6, 162.3, 155.2, 
154.5, 126.1, 113.7, 112.9, 110.9, 101.7, 101.3, 71.4, 71.3, 70.7, 68.3, 62.3, 






         1,2-O-isopropylidene-6-(4-methyl-umbelliferyl)-O-α-D-xylofuranose 
(14). 1H NMR (300 MHz, CDCl3) δ 7.45 (d, J = 8.9 Hz, 1H), 6.88 (dd, J = 8.9, 2.4 
Hz, 1H ), 6.84 (d, J = 2.4 Hz, 1H), 6.1 (d, 1H), 6.01 ( d, J = 3.5 Hz, 1H, H-1), 4.59 
(d, J = 3.8 Hz, 1H, H-2), 4.55 (ddd, J = 11.3, 5.5, 2.7 Hz, 1H. H-4), 4.40 (d, J = 
2.7 Hz, 1H, H-3), 4.32 (ddd, J = 16.5, 10.3, 6.2 Hz, 2H, H-6), 2.77 (s, 1H, OH), 
2.37 (d, 3H), 1.52 (s, 3H), 1.33 (s, 3H); 13C NMR (100 MHz, CDCl3) 161.7, 155.2, 
152.9, 125.8, 114.1, 112.9, 112.3, 105.2, 101.8, 85.5, 78.4, 75.3, 66.4, 29.9, 
27.0, 26.4, 22.1, 18.9; ESI/APCI calcd for C18H20O7+ ([M + H]+) 349.1287; 
measured 349.1295. 
         6-(4-Methyl-umbelliferyl)-O-D-xylofuranose (probe 4).   0.20 g (0.57 
mmol) 1,2-O-isopropylidene-6-(4-methyl-umbelliferyl)-O-α-D-xylofuranose was 
dessovled into a 5mL solution (HOAc:H2O:TFA = 80:20:1) in a 10mL round 
bottom flask. The the solution was heated at 60 °C under reduced pressure 
(rotavapor system) for 2 hours. The completion of the reaction was confirmed by 
TLC (eluted with EtOAc/hexane = 3/7). Then the solvent was removed under 
reduced pressure. 5 mL dichloromethane was added and the solvent was 
removed under reduced pressure, this was repeated 3 times in order to remove 
AcOH. Then the product was pumped dry by oil pump for 24 hours. Pure product 
was obtained after chromatography (Hexane/EtOAc = 100/10 to 0/100, yield 110 
mg, 0.35 mmol, 62%). 1H NMR (300 MHz, CDCl3) δ 7.66 (dd, J = 8.9, 1.7 Hz), 
7.0 - 6.9 (m, 1H), 6.9 – 6.8 (m, 1H), 6.14 (d, J =1.1 Hz), 5.39 (d, J = 4.1 Hz, 0.4 






4.4 – 4.3  (m, 1H), 4.3 – 4.2 (m, 2H), 4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 2.42 (d, 
J =1.1 Hz, 1H ); 13C NMR (100 MHz, CDCl3) for the sugar ring there are two sets 
of peaks since it is a 1:1 mixture of α and β. 162.5, 162.3, 155.1, 154.1, 126.1, 
113.7, 112.8, 110.9, 103.3, 101.3, 96.8, 81.1, 80.2, 77.0, 76.9, 75.9, 75.8, 68.6, 
67.9, 17.4; ESI/APCI calcd for C15H17O7+ ([M + H]+) 309.0947; measured 
309.0959. 
           3-(6-Methoxy-2-naphthalenylmethyl)-O-D-xylofurnose (probe 5).This 
compound was prepared using the similar procedure for preparing probe 4 with 
the isolated yield of 55 %. 1H NMR (300 MHz, MeOH) δ 7.79 (s, 1H), 7.72 (d, J 
=1.7 Hz, 1H), 7.69 (d, J = 2.4 Hz), 7.52 (dd, J = 8.6, 1.7 Hz, 1H), 7.18 (d, J = 2.7 
Hz, 1H), 7.08 (dd, J = 8.9, 1.7 Hz, 1H), 5.01 (d, J = 3.4 Hz, 0.6 Hz, α ), 4.96 (d, 
2H), 4.42 (d, J = 7.2 Hz, β ), 3.87 (s, 3H), 3.8-3.5 (m, 5H), 3.3 – 3.2 (m, 1H); 13C 
NMR (100 MHz, MeOH) for the sugar ring there are two sets of peaks since it is 
a mixture of α and β.157.9, 134.5, 134.4, 129.1, 128.9, 126.8, 126.6, 126.4, 
125.3, 118.5, 105.5, 97.8, 93.1, 84.8, 81.9, 74.9, 74.9, 74.8, 72.5, 70.1, 70.0, 
65.9, 61.9, 54.5; ESI/APCI calcd for C17H20O6+ ([M]+) 320.1260; measured 
320.1263. 
          2-((1-(3,4-dimethoxyphenyl)ethoxy)methyl)-6-methoxynaphthalene 
(probe 10).2-(3,4-dimethoyxphenyl)-ethanol was prepared by reducing 3,4-
dimethoxyacetophenone using NaBH4 in MeOH. 2-bromomethyl-6-methoxy-
naphthalene was prepared by treating 6-methoxynaphthyl-methanol with PBr3 in 






reaction solution until no bubbling. Then the organic layer was washed by Sat. 
NaHCO3 for two times and Brine for one time. The organic layer was dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude 
product was use directly for next step. (0.5 g, 2.7 mmol) 2-(3,4-
dimethoyxphenyl)-ethanol and 1eq. 2-bromomethyl-6-methoxy-naphthalene was 
dissolved in THF, then 10 equiv. of NaH was added. After 6 hours, the reaction 
solution was poured to a flask with ice to quench the reaction. 300 mL of EtOAc 
was added to extract the product. The organic layer was washed by 100 mL 
distilled water, 100 mL 1N HCl and Brine, then dried over Na2SO4.  Filtration and 
concentration of the solvent gave the crude solid product, the solid crude product 
was subjected to purification with gradient silica gel column chromatography 
(Hexance/EtOAc = 100:0 to 40/60) to afford the desired product (Yield 0.69g, 
1.97mmol, 73%). 1H NMR (300 MHz, CDCl3) δ 7.7 – 7.6 (m, 3H), 7.40 (dd, J = 
8.4, 1.8 Hz, 1H), 7.1 – 7.0 (m, 2H), 6.9 – 6.8 (m, 3H), 4.58 – 4.38 (dd, J = 46, 
11.67 Hz, 2H), 4.47 (q, J = 6.54, 1H), 3.92 (s, 3H), 3.90 (s, 3H), 3.89 (s, 3H), 1.49 
(d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3,) δ 157.8, 149.4, 148.6, 136.5, 
134.3, 133.9, 129.5, 128.9, 127.2, 126.8, 126.7, 119.0, 111.1, 109.3, 105.9, 70.5, 
56.1, 56.1, 55.5, 29.9, 24.4; ESI/APCI calcd for C22H24O7+ ([M]+) 352.1673; 
measured 352.1675. 
           1-(3,4-dimethoxyphenyl)-2-(4-methyl-umbelliferoxy)-ethanone (probe 
11). To a cooled (0°C) solution of 3,4-dimethoxyacetophenone (0.50 g, 2.71 
mmol) in diethyl ether (50 mL), bromine (0.26 g, 3.32 mmol) dissolved in ether ( 






and the organic layer was wash with water and brine. Then organic layer was 
dried over sodium sulfate. Filtration and evaporation of the solvent gave a crude 
product which was used directly for the next step. The crude product from last 
step, potassium carbonate (0.56 g, 4.05 mmol) and 4-methylumbelliferone (0.47 
g, 2.73 mmol) was dissolved into 50 mL of acetone. The solution was heated 
under reflux for overnight. Upon completion of the reaction (check by TLC, eluted 
with EtOAc/hexane = 1/9), the solvent was removed by compress air. 100 ml 
EtOAc was added to the crude yellowish solid. After being stirred for half an hour 
in EtOAC, there was still some insoluble yellowish solid which was collected by 
filtration. The insoluble yellowish solid was confirmed as the right product by H 
NMR (Yield 0.78 g, 2.21 mmol, 82%). 1H NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 
8.25, 2.04 Hz, 1H), 7.5 - 7.4 (m, 2H), 7.0 - 6.9 (m, 2H), 6.79 (d, J = 2.76 Hz, 1H), 
6.14 (d, J = 1.38 Hz, 1H), 5.33 (s, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 2.4 (d, 1.38 Hz); 
13C NMR (100 MHz, CDCl3) δ 191.9, 161.3, 161.2, 155.2, 154.5, 152.7, 149.7, 
127.5, 125.9, 122.8, 114.5, 112.9, 112.6, 110.4, 110.4, 102.1, 70.7, 56.4, 56.3, 
18.7; ESI/APCI calcd for C20H18O6+ ([M]+) 354.1103; measured 354.1091. 
           (6-Methoxy-2-naphthalenylmethyl)-β-D-glucopyranoside (probe 14).  
1H NMR (300 MHz, METHANOL-D4) δ 7.8 – 7.7 (m, 3H), 7.48 (dd, J = 8.5, 1.7 
Hz, 1H), 7.20 (d, J = 2.7 Hz, 1H ), 7.10 (dd, J = 8.9, 2.4 Hz), 5.0 – 4.7 (dd, J = 
75.9, 11.7 Hz), 4.32 (d, J = 7.5 Hz, H-1), 3.9 – 3.8 (m, 1H), 3.88 (s, 3H), 3.7 – 3.6 
(m, 1H), 3.4 – 3.2 (m, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 158.1, 134.6, 






70.7, 70.5, 61.6, 54.5; ESI/APCI calcd for C18H22O7Na+ ([M + Na]+) 373.1263; 
measured 373.1273. 
           (6-Methoxy-2-naphthalenylmethyl)-β-D-xylopyranoside (probe 16).1H 
NMR (300 MHz, METHANOL-D4) δ 7.8 – 7.7 (m, 3H), 7.46 (dd, J = 8.6, 1.7 Hz, 
1H), 7.19 (d, J = 2.4 Hz, 1H ), 7.09 (dd, J = 8.9, 2.4 Hz), 4.9 – 4.7 (dd, J = 67.3, 
11.7 Hz), 4.32 (d, J = 7.2 Hz, H-1), 3.9 – 3.8 (m, 1H), 3.88 (s, 3H), 3.6 – 3.4 (m, 
2H), 3.3 – 3.1 (m, 2H); 13C NMR (100 MHz, METHANOL-D4) 134.6, 132.9, 129.1, 
128.9, 126.8, 126.6, 126.57, 118.6, 1015.5, 102.9, 76.6, 73.8, 70.8, 70.1, 65.8, 
54.5; ESI/APCI calcd for C18H22O7Na+ ([M + Na]+) 343.1158; measured 
343.1167. 
        (6-Methoxy-2-naphthalenylmethyl)-β-D-cellubioside (probe 17). 1H NMR 
(300 MHz, METHANOL-D4) δ 7.8 – 7.7 (m, 3H), 7.48 (dd, J = 8.5, 1.7 Hz, 1H), 
7.20 (d, J = 2.7 Hz, 1H), 7.10 (dd, J = 8.9, 2.4 Hz), 5.0 – 4.7 (dd, J = 71.8, 11.7 
Hz), 4. (s, 2H), 4.40 (dd, J = 7.5, 3.1 Hz, 2H), 3.9 – 3.8 (m, 3H), 3.88 (s, 3H), 3.7 
– 3.4 (m, 4H), 3.4 – 3.3 (m, 2H), 3.20 (t, J = 8.6 Hz,1H ); 13C NMR (100 MHz, 
METHANOL-D4) δ 158.1, 134.6, 132.9, 129.2, 128.9, 126.7, 126.6, 118.6, 105.5, 
103.4, 101.9, 79.5, 76.9, 76.6, 75.4, 75.2, 73.7, 70.8, 70.2, 61.2, 60.7, 54.5. 
ESI/APCI calcd for C24H32O12Na+ ([M + Na]+) 535.1791; measured 535.1787.  
            (6-Methoxy-2-naphthalenylmethyl)-2,3,4,6-tetra-O-acetyl-β-D-
glcucopyranoside (8). Bromo-2,3,4,6-acetyl-O-α-D-glucopyranoside was 
prepared by treating 1,2,3,4,6-penta-O-acetyl-D-glucose (0.5 g, 1.28 mmol) with 






as solvent for 2 hours. The reaction mixture was extracted by 100 mL EtOAc and 
the organic layer was washed by distilled water, Sat. NaHCO3 for three times and 
Brine for one time. Then the organic layer was dried over anhydrous Na2SO4 and 
filtered. The bromo-2,3,4,6-acetyl-O-α-D-glucopyranoside was obtained by 
removing the solvent under reduced pressure and used directly for next step. 
Bromo-2,3,4,6-acetyl-O-α-D-glucopyranoside (1.28 mmol) and (6-Methoxy-2-
naphthyl)methanol(0.34 g, 1.8 mmol) and 4 Å MS was stirred in 20 mL of 
anhydrous dichloromethane for 15 minutes before adding in Ag2CO3 (0.49 g, 1.8 
mmol ). The mixture was stirred for overnight before filtered through a syringe 
packed with celite and silica gel. Then the solvent was removed and the crude 
product was loaded to a column and purified with gradient (Hexane/EtOAc = 
100/10 to 50/50). Pure product was obtained (0.41g, 0.79 mmol, 65 % yield over 
two steps). 1H NMR (300 MHz, CDCl3) δ 7.8 – 7.7  (m, 3H), 7.37 (dd, J = 8.3, 1.4 
Hz), 7.2 – 7.1 (m, 2H), 5.70 (d, J = 5.1 Hz, H-1 ),5.22 (t, J = 2.8 Hz, H-2), 4.91 
(dd, J = 9.3, 2.1 Hz, H-3), 4.67 (s, 2H), 4.35 (dd, J = 4.5, 3.1 Hz, H-4), 4.2 – 4.1 
(m, 2H), 3.97 (ddd, J = 9.6, 5.5, 3.5 Hz, H-5), 3.9 (s, 3H), 2.1 – 1.8 (m, 12H); 13C 
NMR (100 MHz, CDCl3)  δ 170.9, 169.9, 169.4, 157.9, 134.3, 132.8, 129.6 128.9, 
127.3, 126.6, 126.5, 121.7, 119.2, 105.9, 97.22, 73.4, 70.3, 68.4, 67.2, 66.3, 
63.3, 55.5, 21.2, 21.0 (3C); ESI/APCI calcd for C26H30O11Na+ ([M + Na]+) m/z 
541.1686; measured m/z 541.1677. 
           (6-Methoxy-2-naphthalenylmethyl)-2,3,4,-tri-O-acetyl-D-
xylopyranoside (10). This compound was prepared using the similar procedure 






CDCl3) The compound was obtained as a mixture of alpha and beta 
conformation (α/β = 1.3/1) δ 7.8 – 7.7 (m, 4.6 H), 7.5 – 7.4 (m, 1.6 H), 7.2 – 7.1 
(m, 3.1 H), 5.7 (d, J = 6.9 Hz,1H, H α-1), 5.58 (d, J = 4.5 Hz, 1.3H,  H β-1), 5.28 
(t, J = 2.8 Hz, 1.3H), 5.20 (t, J = 8.3, 1H), 5.1 – 4.8 (m, 4H), 4.68 (s, 2H), 4.3 – 
4.2 (m, 1.4H), 4.15 (dd, J = 12.0, 5.2 Hz, 1H), 4.0 – 3.9 (m, 1H), 3.90 (s, 5.1H), 
3.71 (dd, J = 12.4, 6.9 Hz, 1.4H), 3.51 (dd, J = 12.0, 8.6 Hz, 1 H ), 2.1 – 2.0 (m, 
21H); 13C NMR (100 MHz, CDCl3) δ 170.1, 170.0, 169.5, 169.3, 169.2, 157.9, 
134.3, 132.8, 129.6, 128.9, 127.3, 126.7, 126.6, 126.1, 125.7, 122.6, 119.1, 
105.9, 96.8, 92.3, 74.5, 71.2, 69.7, 69.6, 68.8, 68.5, 67.6, 65.6, 63.0, 59.9, 55.5, 
22.9 (2C), 21.0, 20.9, 20.87, 20.81; ESI/APCI calcd for C23H26O9Na+ ([M + Na]+) 
m/z 469.1475; measured m/z 469.1468. 
           Methyl-2,3,4-Tri-benzoyl-O-6-(6-Methoxy-2-naphthalenylmethyl)-α-D-
mannopyranoside (13). 6-methoxy-2-naphthalenylmethyl trichloroacetimidate 
(0.33 g, 1 mmol) and methyl 2,3,4-tri-O-benzoyl-α-D-mannopyranoside (0.35 g, 
0.7 mmol), 4 Å molecular sieve in anhydrous dichloromethane (20 mL) was 
stirred for 30 minutes and then cooled to -78 °C. After addition of several drops of 
BF3.Et2O, the reaction mixture was stirred overnight. After completion of the 
reaction (check by TLC, eluted with EtOAc/hexane = 1/9), the reaction mixture 
was filtered through a short column packed with Celite and silica gel. After 
removal of most of the solvent, the crude product was purified with a gradient 
column chromatography (hexance/EtOAc = 100/0 to 75/25) to furnish the desired 
product (0.48 g, 68%). 1H NMR (CDCl3, 300 MHz) δ 8.1-8.0 (m, 2H), 7.82-7.9 (m, 






9.96, 3.09 Hz, 1H, H3), 5.7 (dd, J = 3.45, 1.71 Hz, 1H, H2), 5.0 (d, J = 1.71 Hz, 
1H, H1), 4.71 (dd, J = 26.1, 11.67 Hz, 2H), 4.27 (dt, J = 9.63, 3.45 Hz, 1H, H5), 
3.91 (s, 3H), 3.79 (d, J = 3.75 Hz, 2H, H6), 3.54 (s, 3H); 13C NMR (CDCl3, 75 
MHz) δ 165.8, 165.7, 163.6, 157.8, 134.3, 133.6, 133.4, 133.3, 133.2(2C), 
130.1(2C), 130.0(3C), 129.9, 129.6, 129.6, 129.44, 129.4, 128.7(2C), 128.5(2C), 
128.5(2C), 127.1, 126.80, 126.7, 118.92, 105.9, 98.8, 74.1, 70.7, 70.5, 70.3, 
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SYNTHESIS OF ANTIFUNGALKANAMYCIN A ANALOGS2 
3-1. Abstract  
A concise and novel method for site-selective alkylation of tetraazidokanamycin 
has been developed that leads to the divergent synthesis of three classes of 
kanamycin derivatives. These new amphiphilic kanamycin derivatives bearing 
alkyl chains length of 4, 6, 8, 9, 10, 12, 16 have been synthesized and tested as 
antibiotics. Surprisingly, the antibacterial effect of the synthesized kanamycin 
derivatives decline or disappear compared to the original kanamycin A, but some 







2Coauthored by Qian Zhang,Madher Alfindee, Xinrui Peng, Yukie Kawasaki, Jon Y. Takemoto, 
and Cheng-Wei Tom Chang, Manuscript in preparation. 
 
 







   Fungal diseases are one of the major threats to human health and food 
security.1 Fungal crop diseases like wheat head blight or scab (caused by 
Fusarium graminearum) and stem rust(caused by Pucciniagraminis) result in 
large economic losses and threats to the world’s food supplies.2 Traditional and 
commonly used antifungals such as amphotericinB and azoles are still in use to 
treat invasive fungal infections, andfungicidaltriazoles, 
pyrimidinesandstrobilurinscontinuetobeusedin 
massivequantitiesforwheatandothermajorcrops.3The effectiveness of the current 
antifungals keep decreasing due to fungal resistance, and traditional crop 
antifungals are causing huge disturbances to the natural ecosystem.In 
consequence, there is a growing and urgent need to develop novel and effective 
antifungal agents. 
          Although aminoglycosides are generally known as anti-bacterials, it has 
been reported that certain classical aminoglycosides could inhibit important crop 
pathogenic fungal oomycetes.4A recent report revealed inhibition of plant 
pathogenic oomycetes Phytophora and Pythium sp. by streptomycin, neomycin, 
ribostamycin and paramomycin, although they showed comparatively little activity 
against several other fungal genera. Also there are some structurally unusual 






Five years ago, it was demonstrated in our lab that there is a new possibility of 
antifungal instead of traditional antibacterial capabilities of 
aminoglycosides.Compound FG08 (Scheme 3-1) synthesis was started by 
alkylation of 22 using bromooctane and NaH as the base to afford glycosyl donor 
23. Then stereo-selective glycosylation between pre-prepared glycosyl acceptor 
24 and donor 23 gave compound 25. Deacetylation, Staudinger reduction of 
azido groups and hydrogenolysis of benzyl groups of 25 offered the final 
compound FG08.6Leaf infection assays and greenhouse studies showed that 
FG08 could suppress wheat fungal infections by Fusarium graminearum—the 
causative agent of Fusarium head blight—at concentrations that are minimally 
phytotoxic. Instead of typical aminoglycoside action of ribosomal protein 
translation miscoding, FG08’s antifungal action involves perturbation of the 
plasma membrane.7This antibacterial to antifungal transformation paved the way 
for the development of a new class of aminoglycoside-based fungicides which 
could be useful in treating crop disease. In addition, this strategy is an example 




















1) PMe3, THF, H2O
2) H2, Pd(OH)2/C,
    HOAc/H2O (1/4)
3) Dowex 1X8-200 (Cl-)









































Scheme 3-1: Synthesis of FG08 
 
FG08, with broad-spectrum antifungal properties but did not inhibit tested 
bacterial and mammalian cells, is great start for the study of antifungal 
aminoglycoside. But the long and complicated synthetic route put a huge limit for 
the application of this new chemically modified aminoglycoside. The 
shortcomings of FG08 prompted our search for similar amphiphilic 










3-3. Synthesis Of Kanamycin Derivatives For Converting Antibacterial Agents To 
Antifungal Agents 
              In our recent study for investigation of structure-activity relationship for 
antibacterial to antifungal conversion of Kanamycin B, I have participated in the 
synthesis of compounds FG14-18.The syntheses of the needed glycosyl donors 
for these additional kanamycin analogs began with the preparation of phenyl 3-
azido-3-deoxy-1-thio-β-D-glucopyranoside, 26 and its derivatives, 27 and 28 
(Scheme 3-2). Using a similar approach, compounds 29 and 30 were prepared 
with Bn and octyl group incorporated at O-4 position, respectively. Alkylation of 
29 and acetylation of 30 led to the formation of glycosyl donors, 33c and 33e. 
Using appropriateprotecting groups and protection strategy, glycosyl donor, 33a 
was synthesized from 27 whereas glycosyl donors33dwere prepared from 28. 
Following the glycosylation and deacetylation, compounds were subjected to 
Staudinger reduction and hydrogenolysis, and the desired kanamycin analogs 
were purified by column chromatography using either CG50 (NH4+) resin or silica 














































    DMAP, DCM
2) BnBr, NaH
    TBAI, DMF
3) TsOH-H2O














    DMAP, DCM
2) C8H17Br, NaH
    TBAI, DMF
3) TsOH-H2O

















    MeOH, DCM
2) BnBr, NaH













1) HOAc, TFA, H2O
2) C8H17Br, NaH







1) HOAc, TFA, H2O
2) TrCl, TEA
    DMAP, DCM
3) C8H17Br, NaH
    TBAI, DMF
4) TsOH-H2O




















































1) PMe3, THF, H2O
2) H2, Pd(OH)2/C,
    HOAc/H2O (1/4)






















1) 33a-e, NIS, TMSOTf
    Et2O/CH2Cl2 (3/1)
2) NaOMe, MeOH
4
34a, R1 = C8H17, R2 = Bn, R3 = Bn        76%
34b, R1 = Bn, R2 = C8H17, R3 = H          86%
34c, R1 = Bn, R2 = Bn, R3 = C8H17         64%
34d, R1 = Bn, R2 = C8H17, R3 = C8H17   52%
34e, R1 = C8H17, R2 = C8H17, R3 = H     63%
FG14, R1 = C8H17, R2 = H, R3 = H          95%
FG15, R1 = H, R2 = C8H17, R3 = H          87%
FG16, R1 = H, R2 = H, R3 = C8H17          83%
FG17, R1 = H, R2 = C8H17, R3 = C8H17   76%









Scheme 3-3: Synthesis of FG14-18 
 
For the synthesis of FG14-18, in collaboration with my labmate, it took us almost 
one year to finish the syntheses of the 5 targeted amphiphilic aminoglycosides. 
The objectives of F14-F18 synthesis in the SAR investigation were to understand 
two key points a) importance of 3"-NH2, ( Does it have to be replaced by OH?) 
and b) the effect of multiple octyl groups(Will di-alkylated kanamycin show better 
activity compared to mono-alkylated?) We found that replacing 3"-NH2with a 






we do not need to modify the 3"-NH2.This is a promising result because both 
kanamycin A and Kanamycin B naturally have the 3"-NH2. Compounds 
incorporated with two octyl groups (FG17 and FG18), showed no improvement in 
antifungal activities, but they had enhanced activities against S. aureus 
(ATCC25923). Perhaps, as the lipophilicity increases, these amphiphilic 
aminoglycosides are less fungal-specific and behave like other amphiphilic 
aminoglycosides that contain longer alkyl chain (ex. hexadecyl) and that show 
strong antibacterial activities. All these lessons we learned from the SAR study 
suggest us: For the synthesis of amphiphilic aminoglycosides, we should have a 
chance to modify kanamycin directly while skipping complicated protection steps 
and glycosylation reaction which usually put the limit for the scale of the 
reaction.Also, we would like to start from kanamycin A which is economical and 
available in large quantity. 
    First, we synthesized 1,3,6′,3″-tetraazidokanamycin (will be abbreviated as 
tetraazidokanamycin in the following text) from commercial available kanamycin 
sulfate according to literature report (Scheme 3-4)9.  Azidesserve as a good 
masking group for amines because of its stability in both acid and basic 
conditions.Also the azide could be turned back into amine easily by Staudinger 
reaction.10This reaction has been tested to be relative high yield (~ 75%) and 




































    DCM/H2O
2)CuSO4, K2CO3
    MeOH, H2O
75%
35kanamycin sulfate  
 
Scheme 3-4: Synthesis of 1,3,6′,3″-Tetraazidokanamycin 
 
In an effort to enable the production of amphiphilic aminoglycosides in an easy 
and efficient process, we decided to investigate the feasibility of direct alkylation 
of tetra-azido kanamycin35 (Scheme 3-5). For the test reaction, we use 
tetraazidokanamycin as the substrate, 20 equivalents of NaH as the base and 
1.5 equivalent of bromooctane for octylation. This design is aimed at exploring if 
mono-alkylation of the primary 6″-OH is possible or not. To our delight and 
surprise, we actually could separate threedifferent products from the test 
reaction. The major product is the 36a, 4″, 6″-O-octyl tetra-azido kanamycin. Also 
36b, 6″-O-octyl tetra-azido kanamycin and 36c, 4″-O-octyl tetra-azido kanamycin 
was isolated. Acetylation of the 36a, 36b and 36c offered 37a, 37b, and 37c, 
respectively (Scheme 3-6). The octylation site was confirmed after performingH-
H correlation spectroscopy (COSY) spectrum and the spectrum was provided in 






reaction afford the final amphiphilic aminoglycosides 38a, 38b and 38c (Scheme 
3-7).   
For our own convenience for further research, we have developed a naming 
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K4608 4″,6″-Di-O-octyl kanamycin 
K608 6″-O-Octyl kanamycin 
K408 4″-O-Octyl kanamycin 
 
 
Table 3-1:Example of Naming System for Octylated Kanamycin 
Note: 4 and 6 indicate the site of alkylation (4″ and 6″ are the two alkylation 
sites), 08 stands for the carbon chain length, N3 stands for 1,3,6′,3″-


















































































































































                   R1            R2  
36a            C8H17      C8H17
36b            C8H17      OH
36c            OH          C8H17
                    R1            R2  
K4608         C8H17      C8H17   46%
K608           C8H17      OH        47%
K408           OH          C8H17    91%  
 






Using a three step synthesis, we have successfully obtained three different types 
of amphiphilic aminoglycosides. K4608, K608, and K408 are structurally very 
close to our previously synthesized FG17, FG06 and FG03. The only difference 
is:K4608, K608 and K408 are derivatives from kanamycin A, at 2′ position there 
is OH group; FG17, FG06 and FG03 are derivatives from kanamycin B, at 2′ 
position there is NH2 group (Figure 3-1). We then immediately submitted K4608, 
K608 and K408 for bioactivity testing against F. graminearumand bacteria.The 
minimum inhibitory concentrations (MICs)value are listed in Table 3-2 and the 
results were compared with FG17, FG06 and FG03. From the result of MIC 
values, K4608, K608 and K408 did not show very good antibacterial activity, 
which is consistent with our previous findings that alkylated aminoglycosides are 
not good antibacterial agents. To our delight, K4608, K608 and K408 showed 
even better activity against F. graminearum compared with FG compounds. We 
are extremely happy about the results, because not only did we successfully 
improved the antifungal activity, we have also cut down the synthetic steps to 
only three steps. No complicated protection strategy is needed, and no 
glycosylation step is needed. The most important advantage compared with FG 
























                      R1            R2  
K4608         C8H17      C8H17   
K608           C8H17      OH        


















                      R1            R2  
FG17           C8H17      C8H17   
FG06           C8H17      OH        
FG03           OH          C8H17
Kanamycin B derivatives  
 






F. graminearum  E. coli S. aureus 
FG17 31.3 125 32 
FG06  31.3 ≥250 ≥250 
FG03 7.8 ND ND 
K4608 0.98 ≥250 ≥250 
K608 3.91 ≥250 ≥250 
K408 0.49 ≥250 125 
 







             For the FG project, we have found that shortening the octyl chain to a 
butyl group (FG01) or extending the chain length to a dodecyl group (FG02) 
diminished the antifungal activity. We are wondering if this would happen again if 
butyl group and dodecyl group were attached to kanamycin A.Due to the 
complexity of synthesizing FG compounds,we did not have time to explore more 
alkyl chain length in our previous study. And our results from FG project always 
face the question: Is 8 carbon chain really the best chain length? With this 
promising result from the K4608 compound, we now have the ability to 
synthesize more amphiphilic aminoglycosides with various chain lengths 
following the new synthetic route (Table 3-3). Using the established protocol, 
apart from the alkylation with bromooctane (8 carbon), we also did the alkylation 
of tetraazidokanamycin using 1-bromobutane (4 carbon), 1-bromohexane (6 
carbon), 1-bromoheptane (7 carbon), 1-bromononane (9 carbon), 1-
bromodecane (10 carbon), 1-bromododecane (12 carbon), 1-bromotetradecane 


































































Entry  Alky Bromide 38 (Yield) 39 (Yield) 40 (Yield) 
1 C4H9Br 38a (22) 39a (8a) 40a (22) 
2 C6H13Br 38b (28) 39b (8a) 40b (21) 
3 C7H15Br 38c (30) 39c (9a) 40c (36) 
4 C9H19Br 38d (34) 39d (13) 40d (25) 
5 C10H21Br 38e (30) 39e (8) 40e (24) 
6 C12H25Br 38f (21) 39f (13) 40f (28) 
7 C14H29Br 38g (21) 39g (9a) 40g (16) 
8 C16H33Br 38h (23) 39h (7a) 40h (25) 
Isolated yield. a Estimated from H NMR 
Note: 39 sometimes is inseparable from 40. 
 
Table 3-3:Alkylation of Tetraazidokanamycinwith Various Chain Length 
 
All alkylations with various alkyl bromides were done following this general 
procedure: to a solution of tetraazidokanamycin (0.5 g, 0.85 mmol) 35, in 20 mL 
of anhydrous DMF, NaH (20 equiv.) was added. The reaction mixture was stirred 
for 10 minutes before adding the corresponding alkyl bromide (1.5 equiv.). A 






stirred at room temperature overnight. Completion of the reaction was confirmed 
using TLC (eluted with EtOAc).Then the reaction was quenched by adding 
MeOH (5 mL). The mixture was concentrated and purified with a gradient silica 
gel column chromatography (eluted from EtOAc/Hexane 30:70 to EtOAc/MeOH 
90:10) to obtain three products. The observed polarity of three products was as 
follows: 4"-momo-armed tetraazidokanamycin>6"-mono-armed 
tetraazidokanamycin>> 4", 6"-di-armed tetraazidokanamycin. The big polarity 
difference between mono-armed and di-armed kanamycin makes it very easy to 
separate the di-armed product from the mono-armed product. There is a very 
small polarity difference between 4"-momo-armed tetraazidokanamycin and 6"-
mono-armed tetraazidokanamycin. The silica gel column chromatography 
purification was successful for almost half of the reactions we tried (Table3-3, 
Entry 4, 5 and 6), but in other cases it is challenging to separate the pure 6"-
mono-armed tetraazidokanamycin (Table 3-3, Entry 1, 2, 3, 7 and 8) since this 
type of product is the minor product compared to the other two types. We do 
observe the formation of the 6’’-mono-armed tetraazidokanamycin for all the 
cases, an estimated of compound 39 yield is given according to H NMR if 6"-
mono-armed tetraazidokanamycin is not isolated to good purity . 
           The purified 4"-mono-armed tetraazidokanamycin 40, 6"-mono-armed 
tetraazidokanamycin 39 and 4", 6"-di-armed tetraazidokanamycin 38 were 
submitted for Staudinger reaction to reduce azide back to amine to afford the 
amphiphilic aminoglycosides (Table 3-4). All the purified aminoglycosides were 






















1)PMe3 (5 eq.), THF
2) Dowex 1X8-200 (Cl-)




















Compound Yields (%) 
K4604 71% 
K604 Not Synthesized 
K404 47% 
K4606 48% 
K606 Not Synthesized 
K406 67% 
K4607 89% 

















K614 Not Synthesized 
K414 60% 
K4616 65% 
K616 Not Synthesized 
K416 41% 
 
Table 3-4: Yield of Mono-armed and Di-armed Amphiphilic Aminoglycosides 
after Staudinger Reaction 
 
 
          The growth inhibition activities of these amphiphilic kanamycin A analogs 
were examined against F. graminearum, E. coli (ATCC25922) and S. aureus 
(ATCC25923) and the results are summarized in Table 3-5.  It was clear that the 
presence of 2"-NH2 does not increase the antifungal activity (FG17 vs. K4608, 
FG06 vs. K608, and FG03 vs. K408).  For the amphiphilic aminoglycosides 
alkylated with various chain length, 8 carbon chain was proved to be the best 
chain length even though 6, 7, 9 and 10 carbon alkylated kanamycin did show 
moderate to good antifungal activity. Again, placement of the octyl group at the 






4",6"-di-alkylated kanamycin. Compounds incorporated with two octyl groups 
(K4608, K4609,and K4610)do not showimprovement in antifungal activities 
compared to the corresponding mono-alkylated aminoglycosides, but slight better 
activities against S. aureus(ATCC25923) and E. Coli (ATCC25922). It is also 
shown again that when alkylation chain become too short (shorter than 6) or too 
long (longer than 10), the antifungal activity diminishes or disappears. To convert 
the traditional antibacterial kanamycin A to new types of antifungal agents, 
alkylation with chain length of 6 to 10 would be good choices. Again, 8 carbon 

























F. graminearum  E. coli S. aureus 
1 O-4"& 6" (4) K4604 125 ≥250 ≥250 
2 O-4" (4) K404 ≥500 ≥250 125 
3 O-4"& 6" (6) K4606 15.6 ≥250 64 
4 O-4" (6) K406 31.3 ≥250 64 
5 O-4"& 6" (7) K4607 15.6 125 125 
6 O-4" (7) K407 125 ≥250 125 
7 O-4"& 6" (9) K4608 0.98 ≥250 ≥250 
8 O-6" (9) K608 3.91 ≥250 ≥250 
9 O-4" (9) K408 0.49 ≥250 125 
10 O-4"& 6" (9) K4609 125 16 8 
11 O-6" (9) K609 125 32 ≥250 
12 O-4" (9) K409 62.5 ≥250 ≥250 
13 O-4"& 6" (10) K4610 ≥500 ≥250 16 
14 O-6" (10) K610 62.5 ≥250 64 
15 O-4" (10) K410 62.5 ≥250 125 
16 O-4"& 6" (12) K4612 ≥500 ≥250 64 
17 O-6" (12) K612 250 32 32 
18 O-4" (12) K412 ≥500 125-250 64 
19 O-4"& 6" (14) K4614 ≥500 ≥250 ≥250 






21 O-4"& 6" (16) K4616 ≥500 ≥250 ≥250 
22 O-4" (16) K416 ≥500 32 125 
 
Table 3-5: MIC of Kanamycin A Analogs 
 
                In collaboration with Dr. Takemoto’s lab of the Biology Department, 
Utah State University, the mechanism of FG08’s antifungal property has been 
studied. FG08’s growth inhibitory specificity for fungi is suggested to lie in its 
ability to increase plasma membrane permeability bymechanisms that are 
influenced by the lipid composition of thefungal plasma membrane.  We propose 
that our Kanamycin A analogs probably follow the same mechanism of action as 
FG08 (Kanamycin B analog) due to the structure similarity. These active new 
kanamycin A analogs have broad-spectrum antifungalactivities, almost no 
antibacterial activity that would promote antibioticresistance.They appear to be 













3-4. Conclusions and Significance 
Inspired by the leading compounds FG08 from our previous study,we have 
demonstrated that the amphiphilic aminoglycosides have general potential to be 
converted to antifungal agents. This new type of broad spectrum antifungal 
property is completely different from the original antibacterial activity. Importantly, 
we have shown that our new developed approach, involving a three step reaction 
route, could offer simple and efficient synthesis of amphiphilic aminoglycosides. 
Through this new synthetic route, we have synthesized alkylated 
aminoglycosides with various chain length. Interestingly, we have shown that the 
secondary 4"-OH of the Kanamycin A is more reactive than the primary 6"-
OH.The 4",6" di-armed  kanamycin is not more active compared with the 4" 
mono-armed kanamycin which is consistent with our previous study, 8 carbon 
chain length is the best chain length for yielding antifungal activity. Kanamycin 
alkylated with 6, 7, 9 and 10 carbon chain length also show antifungal activity, 
but the antifungal activity diminish or disappear when the alkyl chain becomes 
too short (shorter than 6) or too long (longer than 10). In conclusion, we have 
provided a possible large scale synthesis route for the preparation of antifungal 
aminoglycosides. These new findings may expedite further research for 
amphiphilic aminoglycosides, whether to use amphiphilic aminoglycosides to 
fight against bacterial resistance or revive traditional amphiphilic aminoglycosides 







3-5. Experimental Section 
Proton magnetic resonance spectra were recorded using JEOL ECX-300, or 
Bruker ARX-400 spectrometer. Chemical shifts were reported as parts per million 
(ppm) downfield from tetramethylsilane in δ unit and coupling constants were 
given in cycles per second (Hz), Signal multiplicities were indicated by s (singlet), 
d (doublet), t (triplet), and q (quartet), m(multiplet). 13C NMR spectra were 
obtained using JEOL ECX-300 at 75 MHz, or Bruker ARX-400 at 100 MHz. 
Routine 13C NMR spectra were fully decoupled by broad-broad WALTZ 
decoupling. All NMR spectra were recorded at ambient temperature. Low-
resolution fast-atom bombardment (LRFAB), high-resolution fast-atom 
bombardment (HRFAB), high-resolution MALDI, chemical ionization (CI), 
atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI) 
were provided by the Mass Spectrometry Facility, University of California, 
Riverside.  
Chemical reagents and chromatography solvents were purchased from 
Aldrich Chemical Co. or Acros Chemcial Co. and were used without purification 
unless otherwise noted.  Dichloromethane was freshly distilled from calcium 
hydride under nitrogen atmosphere. Pyridine and triethylamine were distilled and 
stored over 4Å molecular sieve. Column chromatographic purifications were 
carried out on silica gel 230x450 mesh, Sorbent Tech. Analytical TLC was 
performed on Sorbent Technologies silica gel glass TLC plates. Visualization 






treating with diluted sulfuric acid (5% in methanol) solution or treating in iodine 
chamber, TLC staining for compounds bearing amine were done by treating with 
ninhydrin (in ethanol) and heating. 
           Procedure for Synthesis of 1,3,6′,3″-Tetraazidokanamycin. To a 
solution of NaN3 (25.4 g, 388 mmol) in a mixture of H2O/CH2Cl2 (200 mL, 1:1 v/v) 
at 0°C, Tf2O (33 mL, 199 mmol) was added. The reaction mixture was stirred at 
room temperature for 2 h. After been quenched with saturated aqueous NaHCO3, 
the layers were separated, and the aqueous layer was extracted with CH2Cl2 
(100 mL). The organic layers were combined to afford 200 mL of TfN3 solution, 
which was added to a solution of kanamycin sulfate (9.45 g, 16.2 mmol) in H2O 
(200 mL), MeOH (600 mL), and CuSO4 (250 mg) prepared as a stock solution of 
MeOH/H2O/Et3N (50 mL, 3/3/4 v/v/v). The reaction mixture was stirred at room 
temperature for 2 h. Then solid NaHCO3 (20 g) was added carefully. The mixture 
was filtered through buchner funnel, and the residue organic solvents were 
concentrated by rotavapor. The crude product was purified by column 
chromatography with gradient (EtOAc/MeOH 100:0 to 50:50) to afford 
azidokanamycin, yield 60 - 85%. The synthesized 1,3,6′,3″-tetraazidokanamycin 
was characterized by H NMR and confirmed to be the right compound. 
               Greneral Procedure for O-Alkylation of 1,3,6′,3″-
Tetraazidokanamycin.To a solution of azidokanamycin (0.5 g, 0.85 mmol) in 20 
mL of anhydrous DMF, NaH (20 equiv.) was added. Catalytic amount of TBAI 






adding the corresponding alkyl bromide (1.5 equiv.). The reaction mixture was 
stirred at room temperature overnight. Completion of the reaction was confirmed 
by TLC (Eluted with EtOAc), and the reaction was quenched by adding MeOH (5 
mL). The mixture was concentrated and purified with a gradient column 
chromatography (eluted from EtOAc/Hexane 30:70 to EtOAc/MeOH 90:10) to 
afford three products. All alkylation products were characterized by H NMR, 13C 
NMR and mass spectrum. 
             General Procedure for Staudinger Reaction.The O-alkylated 
tetraazidokanamycin (0.2 g) was dissolved into 20 mL THF in a 50 mL round 
bottom flask. Several drops of water and 5 equiv. of PMe3 (1 M solution in THF) 
was added to the solution. The reaction mixture was heated at 60°C for 2 hours. 
The reaction mixture was concentrated and then diluted with water. After been 
filtered through Celite, the crude product was loaded to a CG50 column (NH4+ 
form) and purified by a mixture of water and ammonium hydroxide (H2O/NH2OH 
100:0 to 50:50) to afford the purified product. The product was concentrated and 
acidified with 5% HOAc in water to afford the acetate salt in water first. Then the 
aqueous solution was removed and re-dissolved into water. Eluting the aqueous 
solution containing acetate salt through ion exchange column (Dowex 1X8 
chloride form) afforded the final product as chloride salt.  
             4″-O-Butyl-1,3,6′,3″-tetraazidokanamycin (K404N3).1H NMR (300 
MHz, METHANOL-D4) δ 5.24 (d,  J = 3.78 Hz, 1H), 5.18 (d,  J = 3.42 Hz, 1H), 
4.0-4.2 (m, 2H), 3.3 - 3.8, (m, 16H), 3.17 (t, J = 9.9 Hz, 1H), 2.3 - 2.4 (m, 1H), 2.0 






NMR (100 MHz, METHANOL-D4) δ 101.17, 98.51, 83.82, 80.35, 76.35, 74.46, 
73.54, 72.65, 72.24(2C), 71.39, 71.10, 70.85, 66.88, 61.02, 60.27, 59.63, 51.52, 
32.331, 29.22, 19.10, 13.01.ESI/APCI calcd for C22H36N12O11Na ([M + Na]+) m/z 
667.2532; measured m/z 667.2516. 
              4″,6″-Di-O-hexyl-1,3,6′,3″-tetraazidokanamycin (K4606N3).1H NMR 
(300 MHz, METHANOL-D4)   δ 5.24 (d,  J = 3.78 Hz, 1H), 5.16 (d,  J = 3.78 Hz, 
1H), 4.1-4.2 (m, 1H), 4.0- 4.1 (m, 1H), 3.3 - 3.7, (m, 18H), 3.18 (t, J = 9.8 Hz, 
1H), 2.3 - 2.4 (m, 1H), 1.5 - 1.6 (m, 5H), 1.2 - 1.4 (m, 12H), 0.89 (t, J = 6.4 Hz, 
6H).; 13C NMR (100 MHz, METHANOL-D4) δ 101.16, 98.44, 83.83, 80.22, 76.65, 
74.40, 73.56,72.65, 72.56, 72.24, 71.40, 71.12, 70.85, 70.49, 68.90, 66.97, 
61.05, 59.63, 51.52, 32.20, 31.63(2C), 30.11, 29.47, 25.87(2C), 22.50(2C), 
13.18(2C).ESI/APCI calcd for C30H52N12O11Na ([M + Na]+) m/z 779.3784; 
measured m/z 779.3785. 
             4″-O-Hexyl-1,3,6′,3″-tetraazidokanamycin (K406N3).1H NMR (300 
MHz, METHANOL-D4) δ 5.23 (d,  J =3.78 Hz, 1H), 5.18 (d,  J =3.78 Hz, 1H), 4.1- 
4.0 (m, 2H), 3.8 - 3.3, (m, 16H), 3.17 (t, J =9.8 Hz, 1H), 2.4 - 2.3 (m, 1H), 1.6 - 
1.5 (m, 3H), 1.4 - 1.2 (m, 6H), 0.89 (t, J =6.4 Hz, 3H); 13C NMR (100 MHz, 
METHANOL-D4) δ 101.18, 98.51, 83.80, 80.37, 76.36, 74.49, 73.55, 72.65, 
72.54, 72.25, 71.42, 71.14, 70.86, 66.91, 61.03, 60.30, 59.64,51.53, 31.63, 
30.16, 29.52, 29.22, 25.71, 22.48, 13.17.ESI/APCI calcd for C24H40N12O11Na ([M 






              4″,6″-Di-O-heptyl-1,3,6′,3″-tetraazidokanamycin (K4607N3).1H NMR 
(300 MHz, METHANOL-D4)  δ 5.24 (d, J = 3.8 Hz, 1H), 5.16 (d, J = 3.8 Hz, 1H), 
4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 18H), 3.18 (t, J = 10.0 Hz, 1H), 
2.34 (ddd, J = 18.9, 9.4, 4.5 Hz, 1H)),1.6 – 1.5 (m, 5H), 1.4 – 1.2 (m, 16H), 0.89 
(t, J = 6.5 Hz, 6H); 13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.5, 83.8, 
80.2, 76.7, 74.4, 73.6, 72.7, 72.7, 72.2, 71.4, 71.1, 70.9, 70.5, 68.9, 66.9, 61.1, 
59.6, 51.5, 31.8(2C), 30.2, 29.5(2C), 29.1(2C), 26.2, 26.0, 22.6(2C), 13.2(2C). 
ESI/APCI calcd for C32H56N12O11Na ([M + Na]+) m/z 807.4084; measured m/z 807.4101. 
             4″-O-Heptyl-1,3,6′,3″-tetraazidokanamycin (K407N3).1H NMR (300 
MHz, METHANOL-D4)  δ 5.24 (d, J = 3.8 Hz, 1H), 5.18 (d, J = 3.8 Hz, 1H), 4.2 – 
4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 16H), 3.18 (t, J = 9.6 Hz, 1H), 2.34 
(ddd, J = 12.7, 9.4, 4.5 Hz, 1H)),1.6 – 1.5 (m, 3H), 1.4 – 1.2 (m, 8H), 0.86 (t, J = 
6.5 Hz, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.5, 83.8, 80.3, 
76.4,74.5, 73.6, 72.7, 72.5, 72.3, 71.4, 71.1, 70.9, 66.9, 61.1, 60.3, 59.7, 51.5, 
32.2, 31.8, 29.5, 29.1, 25.9, 22.4, 13.2. ESI/APCI calcd for C25H42N12O11Na ([M + 
Na]+) m/z 709.2988; measured m/z 709.3000. 
         4″,6″-Di-O-octyl-1,3,6′,3″-tetraazidokanamycin(K4608N3). 1H NMR 
(300 MHz, METHANOL-D4) δ 5.24 (d, J = 3.8 Hz, 1H), 5.17 (d, J = 3.8 Hz, 1H), 
4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 18H), 3.18 (t, J = 10.0 Hz, 1H), 
2.34 (ddd, J = 18.9, 9.4, 4.5 Hz, 1H)),1.6 – 1.5 (m, 5H), 1.4 – 1.2 (m, 20H), 0.88 
(t, J = 6.8 Hz, 6H); 13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.4, 83.8, 






59.6, 51.5, 32.2, 31.8(2C), 30.2, 29.5, 29.4(2C), 29.3(2C), 26.2, 26.1, 22.6(2C), 
13.3(2C). ESI/APCI calcd for C34H60N12O11Na ([M + Na]+) m/z 835.4397; 
measured m/z 835.4397. 
         6″-O-Octyl-1,3,6′,3″-tetraazidokanamycin(K608N3). 1H NMR (300 
MHz, METHANOL-D4) δ ) δ 5.26 (d, J = 4.1 Hz, 1H), 5.19 (d, J = 3.4 Hz, 1H), 4.2 
– 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 17H), 2.34 (ddd, J = 16.8, 8.6, 4.1 
Hz, 1H)),1.6 – 1.5 (m, 3H), 1.4 – 1.2 (m, 10H), 0.86 (t, J = 6.2 Hz, 3H); 13C NMR 
(100 MHz, METHANOL-D4) δ 101.1, 98.4, 83.7, 80.3, 76.4,74.5, 73.6, 72.6, 
72.2, 71.6, 71.1, 70.9, 69.3, 68.8, 67.3, 60.9, 59.6, 51.5, 32.2, 31.8, 29.5, 29.4, 
29.3, 26.0, 22.5, 13.3; ESI/APCI calcd for C26H44N12O11Na ([M + Na]+) m/z 
723.3145; measured m/z 723.3165. 
4″-O-Octyl-1,3,6′,3″-tetraazidokanamycin (K408N3). 1H NMR (300 MHz, 
METHANOL-D4) δ ) δ 5.24 (d, J = 3.8 Hz, 1H), 5.19 (d, J = 3.8 Hz, 1H), 4.2 – 4.1 
(m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 16H), 3.17 (t, J = 9.8 Hz, 1H), 2.34 (ddd, 
J = 16.8, 8.6, 4.1 Hz, 1H)),1.6 – 1.5 (m, 3H), 1.4 – 1.2 (m, 10H), 0.86 (t, J = 6.8 
Hz, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.5, 83.8, 80.4, 76.4, 
74.5, 73.6, 72.7, 72.6, 72.2,  71.4, 71.1, 70.8, 66.9, 61.0, 59.7, 51.5, 32.2, 31.8, 
30.2, 29.5, 29.4, 29.2, 26.1, 22.5, 13.2; ESI/APCI calcd for C26H44N12O11Na ([M + 
Na]+) m/z 723.3145; measured m/z 723.3157. 
            4″,6″-Di-O-nonyl-1,3,6′,3″-tetraazidokanamycin (K4609N3). 1H NMR 
(300 MHz, METHANOL-D4) δ 5.25 (d, J = 3.8 Hz, 1H), 5.17 (d, J = 3.8 Hz, 1H), 
4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 18H ), 3.19 (t, J = 9.8 Hz, 1H), 






6H);13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.4, 83.8, 80.2, 76.7, 74.4, 
73.6, 72.7, 72.6, 72.2, 71.4, 71.1, 70.9, 70.5, 68.9, 66.9, 61.0, 59.6, 51.5, 32.3, 
31.9(2C), 30.2, 29.6(2C), 29.5(2C), 29.4(2C), 29.3, 26.2, 26.1, 22.6(2C), 
13.3(2C); ESI/APCI calcd for C36H64N12O11Na ([M + Na]+) m/z 863.4710; 
measured m/z 863.4710. 
6″-O-Nonyl-1,3,6′,3″-tetraazidokanamycin(K609N3). 1H NMR (300 MHz, 
METHANOL-D4) δ 5.26 (d, J = 3.8 Hz, 1H), 5.18 (d, J = 3.8 Hz, 1H), 4.2 – 4.1 
(m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 17H ), 2.4 – 2.3 (m, 1H), 1.6 – 1.5 (m, 
3H), 1.4 – 1.2 (m, 12H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
METHANOL-D4) δ 101.1, 98.4, 83.7, 80.4, 74.5, 73.6, 72.7, 72.2, 71.6, 71.2, 
71.1, 70.9, 69.3, 68.9, 67.3, 60.9, 59.6, 51.5, 32.2, 31.9, 29.5, 29.45, 29.2, 26.0, 
25.4, 22.5, 13.2; ESI/APCI calcd for C27H46N12O11Na ([M + Na]+) m/z 737.3301; 
measured m/z 737.3316. 
4″-O-Nonyl-1,3,6′,3″-tetraazidokanamycin (K409N3). 1H NMR (300 MHz, 
METHANOL-D4) δ 5.24 (d, J = 4.1 Hz, 1H), 5.18 (d, J = 3.4 Hz, 1H), 4.2 – 4.1 
(m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 16H ), 3.17 (t, J = 9.6 Hz, 1H), 2.4 – 2.3 
(m, 1H), 1.6 – 1.5 (m, 3H), 1.4 – 1.2 (m, 12H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR 
(100 MHz, METHANOL-D4) δ 101.2, 98.5, 83.8, 80.4, 76.4, 74.5, 73.6, 72.7, 
72.5(2C), 72.2, 71.4, 71.2, 70.9, 66.9, 61.0, 59.7, 51.5, 32.2, 31.8, 30.2, 29.5, 
29.4, 29.2, 26.0, 22.5, 13.2; ESI/APCI calcd for C27H46N12O11Na ([M + Na]+) m/z 






            4″,6″-Di-O-decyl-1,3,6′,3″-tetraazidokanamycin(K4610N3).1H NMR 
(300 MHz, METHANOL-D4) δ 5.24 (d, J = 3.8 Hz, 1H), 5.16 (d, J = 3.8 Hz, 1H), 
4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 18H ), 3.19 (t, J = 10.0 Hz, 1H), 
2.4 – 2.3 (m, 1H), 1.6 – 1.5 (m, 5H), 1.4 – 1.2 (m, 28H), 0.88 (t, J = 6.5 Hz, 6H); 
13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.4, 83.8, 80.2, 76.7, 74.4, 73.6, 
72.7, 72.6, 72.3, 71.4, 71.1, 70.9, 70.5, 68.9, 66.9, 61.0, 59.6, 51.5, 32.2, 
31.9(2C), 30.1, 29.6(5C), 29.4(2C), 29.3(2C), 26.2, 26.1, 22.6(2C), 13.3(2C); 
ESI/APCI calcd for C38H68N12O11Na ([M + Na]+) 891.5023; measured m/z 
891.4995. 
            6″-O-Decyl-1,3,6′,3″-tetraazidokanamycin (K610N3). 1H NMR (300 
MHz, METHANOL-D4) δ 5.26 (d, J = 3.8 Hz, 1H), 5.19 (d, J = 3.8 Hz, 1H), 4.2 – 
4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 17H ), 2.4 – 2.3 (m, 1H), 1.6 – 1.5 
(m, 3H), 1.4 – 1.2 (m, 14H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
METHANOL-D4) δ 101.2, 98.4, 83.8, 80.2, 76.7, 74.4, 73.6, 72.7, 72.6, 71.4, 
71.1, 70.9, 70.5, 68.9, 67.0, 61.0, 59.6, 51.5, 32.2, 31.9, 29.6(2C), 29.4, 29.3, 
26.2, 26.1, 22.5, 13.3; ESI/APCI calcd for C28H48N12O11Na ([M + Na]+) 751.3466; 
measured m/z 751.3466. 
             4″-O-Decyl-1,3,6′,3″-tetraazidokanamycin(K410N3). 1H NMR (300 
MHz, METHANOL-D4) δ 5.24 (d, J = 4.1 Hz, 1H), 5.18 (d, J = 3.5 Hz, 1H), 4.2 – 
4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 16H ), 3.17 (t, J = 9.8 Hz, 1H), 2.4 – 
2.3 (m, 1H), 1.6 – 1.5 (m, 3H), 1.4 – 1.2 (m, 18H), 0.88 (t, J = 6.5 Hz, 3H); 13C 






72.7, 72.5, 72.2, 71.4, 71.1, 70.9, 66.9, 61.0, 60.3, 59.6, 51.5, 32.2, 31.8, 29.6, 
29.5, 29.4, 29.2, 26.0, 25.4, 22.5, 13.2; ESI/APCI calcd for C28H48N12O11Na ([M + 
Na]+) 751.3466; measured m/z 751.3477. 
            4″,6″-Di-O-dodecyl-1,3,6′,3″-tetraazidokanamycin (K4612N3).1H NMR 
(300 MHz, METHANOL-D4) δ 5.24 (d, J = 3.8 Hz, 1H), 5.16 (d, J = 3.8 Hz, 1H), 
4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 18H ), 3.19 (t, J = 10.0 Hz, 1H), 
2.4 – 2.3 (m, 1H), 1.6 – 1.5 (m, 5H), 1.4 – 1.2 (m, 36H), 0.88 (t, J = 7.2 Hz, 6H); 
13C NMR (100 MHz, METHANOL-D4) δ 101.2, 98.4, 83.8, 80.2, 76.7, 74.4, 73.6, 
72.7, 72.6, 72.2, 71.4, 71.1, 70.9, 70.5, 68.9, 66.9, 61.0, 59.6, 51.5, 32.2, 
31.9(2C), 30.1, 29.6(9C), 29.4(2C), 29.3(2C), 26.2, 26.1, 22.6(2C), 13.3(2C); 
ESI/APCI calcd for C42H75N12O11Na ([M + Na]+) 947.5649; measured m/z 
947.5681. 
            6″-O-Dodecyl-1,3,6′,3″-tetraazidokanamycin (K612N3).1H NMR (300 
MHz, METHANOL-D4) δ 5.26 (d, J = 3.8 Hz, 1H), 5.16 (d, J = 3.8 Hz, 1H), 4.2 – 
4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 17H ), 2.4 – 2.3 (m, 1H), 2.1 – 2.0 
(m, 1H), 1.6 – 1.5 (m, 2H), 1.4 – 1.2 (m, 18H), 0.88 (t, J = 6.2 Hz, 3H); 13C NMR 
(100 MHz, METHANOL-D4) δ 101.1, 98.4, 83.7, 80.3, 74.5, 73.6, 72.7, 72.2, 
71.6, 71.2, 71.1, 70.9, 69.3, 68.9, 67.3, 60.9, 59.6, 51.5, 32.2, 31.9, 29.6(6C), 
29.3, 26.0, 22.5, 13.2; ESI/APCI calcd for C30H52N12O11Na ([M + Na]+) 779.3711; 
measured m/z 779.3797. 
             4″-O-Dodecyl-1,3,6′,3″-tetraazidokanamycin (K412N3).1H NMR (300 






4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 16H), 3.17 (t, J = 9.8 Hz, 1H), 2.4 – 
2.3 (m, 1H), 2.1 – 2.0 (m, 1H), 1.6 – 1.5 (m, 2H), 1.4 – 1.2 (m, 18H), 0.88 (t, J = 
6.5 Hz, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 101.1, 98.5, 83.8, 80.3, 
76.4, 74.5, 73.6, 72.7, 72.5, 72.2, 71.4, 71.2, 70.9, 66.9, 61.0, 60.3, 59.7,  51.5, 
32.2, 31.9, 30.2, 29.6(4C), 29.4, 29.2, 26.0, 22.5, 13.2; ESI/APCI calcd for 
C30H52N12O11Na ([M + Na]+) 779.3711; measured m/z 779.3791. 
            4″,6″-Di-O-tetradecyl-1,3,6′,3″-tetraazidokanamycin (K4614N3).1H 
NMR (300 MHz, METHANOL-D4) δ 5.25 (d,  J = 3.78 Hz, 1H), 5.18 (d,  J = 3.78 
Hz, 1H), 4.1-4.2 (m, 1H), 4.0- 4.1 (m, 1H), 3.3 - 3.7, (m, 18H), 3.20 (t, J = 9.6 Hz, 
1H), 2.3 - 2.4 (m, 1H), 1.5 - 1.6 (m, 5H), 1.2 - 1.4 (m, 44H), 0.89 (t, J = 6.6 Hz, 
6H); 13C NMR (100 MHz, METHANOL-D4) δ 101.13, 98.39, 83.79, 80.17, 78.27, 
76.65, 74.36, 73.56, 72.64, 72.24, 71.37, 71.12, 70.84, 70.48, 68.90, 66.97, 
61.02, 59.62, 51.62, 32.27, 31.25(2C), 30.15(2C), 29.66(10C), 29.55(2C), 
29.43(2C), 29.35(2C), 26.28, 26.07, 22.59(2C), 13.71(2C); ESI/APCI calcd for 
C46H84N12O11Na ([M + Na]+) 1003.6275; measured m/z 1003.6308. 
             4″-O-Tetradecyl-1,3,6′,3″-tetraazidokanamycin (K414N3).1H NMR 
(300 MHz, METHANOL-D4) δ 5.25 (d,  J = 3.78 Hz, 1H), 5.18 (d,  J = 3.78 Hz, 
1H), 4.0- 4.1 (m, 2H), 3.3 - 3.8, (m, 16H), 3.18 (t, J = 9.9 Hz, 1H), 2.3 - 2.4 (m, 
1H), 1.5 - 1.6 (m, 3H), 1.2 - 1.4 (m, 22H), 0.89 (t, J = 6.5 Hz, 3H); 13C NMR (100 
MHz, METHANOL-D4) δ 101.14, 98.43, 83.82, 80.17, 76.64, 74.38, 73.56,72.66, 






30.10, 29.60(6C), 29.43, 29.29, 26.23, 26.03, 22.54, 13.71; ESI/APCI calcd for 
C32H56N12O11Na ([M + Na]+) 807.4084; measured m/z 807.4084. 
              4″,6″-Di-O-hexadecyl-1,3,6′,3″-tetraazidokanamycin (K4616N3).1H 
NMR (300 MHz, METHANOL-D4) δ 5.24 (d, J = 3.8 Hz, 1H), 5.18 (d, J = 3.8 Hz, 
1H), 4.2 – 4.1 (m, 1H), 4.1 – 4.0 (m, 1H), 3.8 – 3.3 (m, 18H ), 3.16 (t, J = 9.6 Hz, 
1H), 2.4 – 2.3 (m, 1H), 1.6 – 1.5 (m, 5H), 1.4 – 1.2 (m, 52H), 0.88 (t, J = 6.9 Hz, 
6H); 13C NMR (100 MHz, METHANOL-D4) δ 101.1, 98.3, 83.8, 80.2, 76.7, 74.3, 
73.6, 72.6(2C), 72.2, 71.4, 71.1, 70.9, 70.5, 68.9, 66.9, 60.9, 59.6, 51.5, 32.3, 
31.9(2C), 30.2, 29.7(15), 29.5(2C), 29.48(2C), 29.4(2C), 26.3, 26.1, 22.6(2C), 
13.4(2C); ESI/APCI calcd for C50H92N12O11Na ([M + Na]+) 1059.6901; measured 
m/z 1059.6921. 
                4″-O-Hexadecyl-1,3,6′,3″-tetraazidokanamycin (K416N3).1H NMR 
(300 MHz, METHANOL-D4) δ 5.24 (d, J = 3.8 Hz, 1H), 5.18 (d, J = 3.8 Hz, 1H), 
4.1 – 4.0 (m, 2H), 3.8 – 3.3 (m, 18H ), 3.16 (t, J = 9.6 Hz, 1H), 2.4 – 2.3 (m, 1H), 
1.6 – 1.5 (m, 3H), 1.4 – 1.2 (m, 26H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (100 
MHz, METHANOL-D4) δ 102.5, 99.9, 85.1, 81.7, 77.7, 75.8, 74.9, 74.1, 74.0, 
73.9, 73.6, 72.8, 72.5, 72.2, 68.3, 62.4, 61.6, 61.0, 52.9, 33.6, 33.2, 31.5, 
30.9(7C), 30.7, 30.6, 27.4, 23.9, 14.6; ESI/APCI calcd for C34H60N12O11Na ([M + 
Na]+) 835.4397; measured m/z 835.4416. 
   4″,6″-Di-O-butyl kanamycin(K4604).1H NMR (300 MHz, D2O) δ 5.47 (d,  J = 
3.78 Hz, 1H), 4.96 (d,  J = 3.78 Hz, 1H), 3.3 – 4.1 (m, 19H), 3.0 - 3.1 (m, 1H), 2.3 






6H).; 13C NMR (100 MHz, D2O) δ 101.64, 96.87, 84.46, 79.36, 74.01, 73.51, 
73.44, 73.19, 72.31, 71.07(2C), 71.00, 68.82, 68.47, 68.17, 54.51, 50.26, 48.25, 
40.57, 31.51, 30.91, 28.84, 18.97, 18.79, 13.42(2C).ESI/APCI calcd for 
C26H53N4O11 ([M + H]+) 597.3705; measured m/z 597.3701. 
               4″-O-Buty kanamycin (K404).1H NMR (300 MHz, D2O) ) δ 5.44 (d,  J = 
3.78 Hz, 1H), 5.00 (d,  J = 3.78 Hz, 1H), 3.2 – 4.0 (m, 17H), 3.0 - 3.1 (m, 1H), 2.4 
- 2.5 (m, 1H), 1.7 - 1.8 (m, 1H), 1.4 - 1.5 (m, 3H), 1.1 - 1.3 (m, 2H), 0.7 - 0.8 (t, J 
= 7.56 Hz, 3H); 13C NMR (100 MHz, D2O) δ 101.60, 96.09, 84.12, 78.59, 73.59, 
73.44, 72.51, 72.47, 72.35, 72.22, 71.90(2C), 68.88, 68.31, 59.87, 54.40, 49.97, 
40.46, 31.50, 27.79, 18.68, 13.33.; ESI/APCI calcd for C22H45N4O11 ([M + H]+) 
541.3079; measured m/z 541.3082. 
   4″,6″-Di-O-hexyl kanamycin(K4606).1H NMR (300 MHz, D2O) δ 5.52 (d,  J = 
4.11 Hz, 1H), 5.16 (d,  J = 3.45 Hz, 1H), 3.3 – 4.1 (m, 19H), 3.0 - 3.1 (m, 1H), 2.4 
- 2.5 (m, 1H), 1.8 - 1.9 (m, 1H), 1.4 - 1.5 (m, 5H), 1.1 - 1.3 (m, 12H), 0.7 - 0.8 (m, 
6H); 13C NMR (100 MHz, D2O) δ 100.81, 97.09, 83.89, 78.27, 73.76, 73.67, 
73.28, 72.12, 71.68, 71.11, 71.03, 71.00, 68.88, 68.31, 68.26, 54.48, 50.06, 
48.24, 40.56, 31.25(2C), 29.31, 28.82, 27.86, 25.51, 25.16, 22.35(2C), 
13.71(2C).ESI/APCI calcd for C30H61N4O11 ([M + H]+) 653.4331; measured m/z 
653.4324. 
               4″-O-Hexyl kanamycin (K406).1H NMR (300 MHz, D2O) ) δ 5.44 (d,  J 
= 3.78 Hz, 1H), 5.00 (d,  J = 3.78 Hz, 1H), 3.2 – 4.0 (m, 17H), 3.0 - 3.1 (m, 1H), 






(t, J = 7.56 Hz, 3H); 13C NMR (100 MHz, D2O) δ 101.60, 96.09, 84.12, 78.59, 
73.59, 73.44, 72.51, 72.47, 72.35, 72.22, 71.90(2C), 68.88, 68.31, 59.87, 54.40, 
49.97, 40.46, 31.50, 27.79, 18.68, 13.33; ESI/APCI calcd for C24H49N4O11 ([M + 
H]+) 569.3392; measured m/z 569.3391. 
         4″,6″-Di-O-heptyl kanamycin(K4607).1H NMR (300 MHz, D2O) δ 5.51 (d, 
J = 3.4 Hz, 1H), 4.98 (d, J = 3.4 Hz, 1H), 4.1 – 3.3 (m, 20H), 3.1 – 3.0 (m, 1H), 
2.5 – 2.4 (m, 1H), 1.9 – 1.8 (m, 1H), 1.6 – 1.5 (m, 4H), 1.3 – 1.1 (m, 16H), 0.75 (t, 
J = 6.5 Hz, 6H); 13C NMR (100 MHz, D2O) δ 100.8, 96.7, 83.9, 78.4, 73.8, 73.0, 
72.3, 71.8, 71.2, 71.0, 70.9,  68.9, 68.4, 68.3, 68.2, 54.5, 50.1, 48.1, 40.5, 31.4, 
31.35, 29.3, 28.8, 28.6(2C), 27.9, 25.7, 25.3, 22.2(2C), 13.7(2C). ESI/APCI calcd 
for C32H65N4O11 ([M + H]+) 681.4644; measured m/z 681.4643. 
               4″-O-Heptyl kanamycin (K407).1H NMR (300 MHz, D2O) δ 5.52 (d, J = 
4.1 Hz, 1H), 5.00 (d, J = 3.8 Hz, 1H), 4.0 – 3.2 (m, 18H), 3.1 – 3.0 (m, 1H), 2.6 – 
2.5 (m, 1H), 1.9 – 1.8 (m, 1H), 1.5 – 1.4 (m, 2H), 1.2 – 1.1 (m, 8H), 0.75(t, J = 6.9 
Hz, 3H); 13C NMR (100 MHz, D2O) δ 100.6, 96.1, 84.1, 78.5, 73.9, 73.7, 72.5, 
72.3, 72.25, 70.9(2C), 68.9, 68.3, 59.9, 54.4, 49.9, 47.8, 40.5, 31.2, 29.4, 28.5, 
27.8, 25.2, 22.1, 13.6; ESI/APCI calcd for C25H51N4O11 ([M + H]+) 583.3549; 
measured m/z 583.3570. 
              4″,6″-Di-O-octyl kanamycin (K4608).1H NMR (300 MHz, METHANOL-
D4) δ 5.59 (d, J = 3.8 Hz, 1H), 5.10 (d, J = 3.8 Hz, 1H), 4.1 – 3.4 (m, 20H), 3.0 – 
2.9 (m, 1H), 2.6 – 2.5 (m, 1H), 2.1 – 2.0 (m, 1H), 1.6 – 1.5 (m, 4H), 1.4 – 1.2 (m, 






78.2, 73.8, 73.7, 72.0, 71.7(2C), 71.2, 68.9, 68.4, 68.0, 54.5, 50.1, 48.50, 48.24, 
43.9, 40.7, 31.97(2C), 30.3, 29.5(3C), 29.2, 26.5, 26.2, 25.8, 25.2, 22.8(2C), 
14.03(2C). ESI/APCI calcd for C34H69N4O11 ([M + H]+) 709.4957; measured m/z 
709.4962. 
                6″-O-Octyl kanamycin (K608). 1H NMR (300 MHz, D2O) δ 5.53 (d, J = 
3.8 Hz, 1H), 5.00 (d, J = 3.8 Hz, 1H), 4.0 – 3.2 (m, 18H), 3.1 – 3.0 (m, 1H), 2.5 – 
2.4 (m, 1H), 1.9 – 1.8 (m, 1H), 1.5 – 1.4 (m, 2H), 1.4 – 1.2 (m, 10H), 0.74 (t, J = 
6.9 Hz, 3H); 13C NMR (100 MHz, D2O) δ 100.8, 96.4, 84.1, 77.9, 73.1, 72.3, 72.2, 
72.0(2C), 71.1, 68.9, 68.6, 68.4, 65.9, 55.3, 50.1, 48.2, 40.7, 31.4, 31.3, 28.8, 
28.7, 28.6, 25.4, 22.3, 13.8; ESI/APCI calcd for C26H53N4O11 ([M + H]+) 597.3705; 
measured m/z 597.3705. 
4″-O-Octyl kanamycin (K408). 1H NMR (300 MHz, D2O) δ 5.44 (d, J = 3.8 Hz, 
1H), 5.00 (d, J = 3.8 Hz, 1H), 4.0 – 3.2 (m, 18H), 3.1 – 3.0 (m, 1H), 2.5 – 2.4 (m, 
1H), 1.9 – 1.8 (m, 1H), 1.5 – 1.4 (m, 2H), 1.2 – 1.1 (m, 10H), 0.74 (t, J = 6.9 Hz, 
3H); 13C NMR (100 MHz, D2O) δ 100.6, 96.1, 84.1, 78.4, 73.8, 73.7, 72.5, 72.3, 
72.2, 72.0, 70.9, 68.8, 68.3, 59.9, 54.4, 49.9, 47.8, 40.5, 31.2, 29.3, 28.7, 28.5, 
27.7, 25.2, 22.2, 13.6; ESI/APCI calcd for C26H53N4O11 ([M + H]+) 597.3705; 
measured m/z 597.3697. 
              4″,6″-Di-O-nonyl kanamycin (K4609).1H NMR (300 MHz, 
METHANOL-D4) δ 5.57 (d, J = 3.8 Hz, 1H), 5.09 (d, J = 3.4 Hz, 1H), 4.1 – 3.0 
(m, 21H), 2.5 – 2.4 (m, 1H), 2.0 – 1.9 (m, 1H), 1.6 – 1.5 (m, 4H), 1.3 – 1.2 (m, 






95.2, 84.3, 78.5, 74.0, 73.2, 72.9, 72.3, 71.9, 71.85, 71.8(2C), 71.5, 69.1, 68.9, 
68.7, 55.0, 50.4, 41.1, 31.9(2C), 29.8, 29.6(3C), 29.5(2C), 29.3(2C), 27.7, 26.2, 
25.9, 22.5(2C), 13.2(2C). ESI/APCI calcd for C36H73N4O11 ([M + H]+) 737.5270; 
measured m/z 737.5293. 
               6″-O-Nonyl kanamycin (K609).1H NMR (300 MHz, D2O) δ 5.52 (d, J = 
3.4 Hz, 1H), 4.99 (d, J = 3.8 Hz, 1H), 4.0 – 3.0 (m, 19H), 2.5 – 2.4 (m, 1H), 1.9 – 
1.7 (m, 1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 12H), 0.75 (t, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, D2O) δ 100.7, 96.6, 84.3, 78.5, 73.1, 72.3, 72.2, 72.9, 71.9, 
71.0, 68.9, 68.5, 68.3, 65.9, 55.2, 50.1, 48.2, 40.6, 31.4, 28.9, 28.8, 28.7, 25.3, 
25.4, 22.3, 13.6; ESI/APCI calcd for C27H55N4O11 ([M + H]+) 611.3862; measured 
m/z 611.3862. 
4″-O-Nonyl kanamycin (K409).1H NMR (300 MHz, D2O) δ 5.43 (d, J = 3.8 Hz, 
1H), 4.99 (d, J = 3.4 Hz, 1H), 4.0 – 3.0 (m, 23H), 2.3 – 2.2 (m, 1H), 1.7 – 1.6 (m, 
1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 12H), 0.75 (t, J = 6.9 Hz, 3H); 13C NMR (100 
MHz, D2O) δ 100.5, 96.9, 84.9, 80.5, 74.3, 73.7, 73.2, 72.4, 72.1, 71.1, 71.0, 
68.8, 68.7, 59.9, 54.5, 50.3, 48.2, 40.5, 31.3, 29.8, 29.4, 28.8, 28.7, 28.6, 25.3, 
22.2, 13.6; ESI/APCI calcd for C27H55N4O11 ([M + H]+) 611.3862; measured m/z 
611.3868. 
              4″,6″-Di-O-decyl kanamycin (K4610).1H NMR (300 MHz, METHANOL-
D4) δ 5.57 (d, J = 3.8 Hz, 1H), 5.09 (d, J = 3.4 Hz, 1H), 4.1 – 3.0 (m, 21H), 2.5 – 
2.4 (m, 1H), 2.0 – 1.9 (m, 1H), 1.6 – 1.5 (m, 4H), 1.3 – 1.2 (m, 28H), 0.87 (t, J = 






74.1, 73.2, 72.9, 72.4, 71.9, 71.8(3C), 71.5, 69.1, 68.9, 68.7, 55.1, 50.4, 41.1, 
31.9(2C), 29.9, 29.6(5C), 29.5(2C), 29.3(2C), 28.1, 26.2, 25.9, 22.5(2C), 
13.2(2C). ESI/APCI calcd for C38H77N4O11 ([M + H]+) 765.5583; measured m/z 
765.5569. 
                6″-O-Decyl kanamycin (K610).1H NMR (300 MHz, D2O) δ 5.52 (d, J = 
3.4 Hz, 1H), 4.99 (d, J = 3.8 Hz, 1H), 4.0 – 3.0 (m, 19H), 2.5 – 2.4 (m, 1H), 1.9 – 
1.7 (m, 1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 14H), 0.74 (t, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, D2O) δ 100.7, 96.6, 84.3, 78.5, 73.1, 72.3, 72.2, 71.9, 71.0(2C), 
68.9, 68.5, 68.3, 65.9, 55.2, 50.1, 48.2, 40.6, 31.4, 28.9, 28.87(2C), 28.8, 28.7, 
28.3, 25.4, 22.3, 13.7; ESI/APCI calcd for C28H57N4O11 ([M + H]+) 652.4081; 
measured m/z 652.4016. 
               4″-O-Decyl kanamycin (K410).1H NMR (300 MHz, D2O) δ 5.45 (d, J = 
4.1 Hz, 1H), 5.00 (d, J = 3.8 Hz, 1H), 4.0 – 3.0 (m, 19H), 2.5 – 2.4 (m, 1H), 1.9 – 
1.8 (m, 1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 14H), 0.75 (t, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, D2O) δ 100.6, 96.4, 84.3, 74.0, 73.7, 72.7, 72.4, 72.2, 71.1, 
70.9, 68.9, 68.5, 68.4,  68.3, 55.2, 54.5, 50.1, 47.9, 40.5, 31.4, 29.4, 28.9, 
28.7(2C), 28.3, 25.3, 22.2, 13.6; ESI/APCI calcd for C28H57N4O11 ([M + H]+) 
652.4018; measured m/z 652.4036. 
              4″,6″-Di-O-dodecyl kanamycin (K4612).1H NMR (300 MHz, 
METHANOL-D4) δ 5.64 (d, J = 3.8 Hz, 1H), 5.05 (d, J = 3.8 Hz, 1H), 4.0 – 3.2 
(m, 20H), 3.2 – 3.1 (m, 1H), 2.5 – 2.4 (m, 1H), 2.0 – 1.9 (m, 1H), 1.6 – 1.5 (m, 






METHANOL-D4) δ 100.9, 98.0, 83.8, 77.0, 73.9, 73.2, 72.9, 72.1, 71.7(3C), 71.3, 
69.1, 68.4,  63.6, 54.6, 50.1, 40.8, 32.2(2C),  30.2(8C), 29.8(2C), 29.3, 29.1, 
29.0, 26.4(2C), 25.9, 25.3, 22.9(2C), 14.1(2C); ESI/APCI calcd for C42H85N4O11 
([M + H]+) 821.6209; measured m/z 821.6208. 
                6″-O-Dodecyl kanamycin (K612).1H NMR (300 MHz, D2O) δ 5.51 (d, 
J = 4.1 Hz, 1H), 4.99 (d, J = 3.8 Hz, 1H), 4.0 – 3.0 (m, 19H), 2.5 – 2.4 (m, 1H), 
1.9 – 1.8 (m, 1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 18H), 0.74 (t, J = 6.8 Hz, 3H); 
13C NMR (100 MHz, D2O) δ 100.8, 96.5, 84.1, 78.1, 72.9, 72.3, 72.1, 71.9(2C), 
70.9, 68.9, 68.4, 68.3, 65.7, 55.2, 49.9, 48.0, 40.6, 31.4, 28.9(6C), 28.7, 27.8, 
25.3, 22.2, 13.6; ESI/APCI calcd for C30H61N4O11 ([M + H]+) 653.4331; measured 
m/z 653.4342. 
               4″-O-Dodecyl kanamycin (K412). 1H NMR (300 MHz, METHANOL-
D4) δ 5.53 (d, J = 3.8 Hz, 1H), 5.15 (d, J = 3.8 Hz, 1H), 4.0 – 3.0 (m, 19H), 2.5 – 
2.4 (m, 1H), 2.0 – 1.9 (m, 1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 18H), 0.86 (t, J = 
7.2 Hz, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 100.2, 94.1, 84.5, 78.7, 
74.7, 73.4, 73.0, 71.9(2C), 71.7, 71.3, 69.1, 68.9, 60.7, 54.8, 50.1, 47.2, 40.9, 
31.9, 29.9, 29.5(5C), 29.3, 25.8, 22.5, 13.2; ESI/APCI calcd for C30H61N4O11 ([M 
+ H]+) 653.4331; measured m/z 653.4337. 
               4″,6″-Di-O-tetradecyl kanamycin(K4614).1H NMR (300 MHz, D2O) δ 
5.58 (d,  J = 3.78 Hz, 1H), 5.10 (d,  J = 3.78 Hz, 1H), 3.4-4.2 (m, 19H), 3.0- 3.1 
(m, 1H), 2.9 - 3.0, (m, 1H), 2.5 - 2.6 (m, 1H), 1.5 - 1.7 (m, 5H), 1.2 - 1.4 (m, 44H), 






73.97, 73.19, 72.92, 72.17, 71.94, 71.76(2C), 71.49(2C), 69.11, 68.93, 68.65, 
55.01, 50.35, 41.03, 31.90, 29.83(13C), 29.61(2C), 29.51(2C), 29.31(2C), 27.67, 
26.28, 25.92, 22.56(2C), 13.18(2C).ESI/APCI calcd for C46H93N4O11 ([M + H]+) 
877.6835; measured m/z 877.6834. 
               4″-O-Tetradecyl kanamycin (K414).1H NMR (300 MHz, D2O) ) δ 5.55 
(d,  J = 3.78 Hz, 1H), 5.00 (d,  J = 3.42 Hz, 1H), 3.4-4.2 (m, 17H), 3.29 (t, J =9.9 
Hz, 1H), 2.9 - 3.0, (m, 1H), 2.4 - 2.5 (m, 1H), 2.4 - 2.5 (m, 1H), 1.5 - 1.7 (m, 3H), 
1.2 - 1.4 (m, 22H), 0.89 (t, J = 6.5 Hz, 3H); 13C NMR (100 MHz, D2O) δ 100.77, 
95.68, 84.84, 79.63, 74.14, 73.17, 72.92, 72.56, 71.91, 71.79(2C), 71.49, 
69.04(2C), 68.67, 55.08, 50.47, 41.00, 31.78, 29.80, 29.83(6C), 29.48, 29.28, 
26.25, 25.88, 22.53, 13.27.; ESI/APCI calcd for C37H65N4O11 ([M + H]+) 681.4644; 
measured m/z 681.4665. 
             4″,6″-Di-O-hexadecyl kanamycin (K4616).1H NMR (300 MHz, 
METHANOL-D4) δ 5.56(d, J = 3.8 Hz, 1H), 5.09 (d, J = 3.8 Hz, 1H), 4.0 – 3.0 (m, 
21H), 2.5 – 2.4 (m, 1H), 2.0 – 1.9 (m, 1H), 1.6 – 1.5 (m, 4H), 1.3 – 1.2 (m, 52H), 
0.88 (t, J = 6.8 Hz, 6H); 13C NMR (101 MHz, METHANOL-D4) δ 100.8, 94.8, 
84.3, 78.7, 73.9, 73.2, 72.9, 72.1, 71.9, 71.8(2C), 71.48, 71.44, 71.3, 69.1, 68.9, 
68.7, 55.0, 50.4, 31.8(2C), 29.8, 29.6(18C), 29.5(2C), 29.3(2C), 26.3, 25.9, 
22.5(2C), 13.2(2C); ESI/APCI calcd for C50H101N4O11 ([M + H]+) 933.7461; 
measured m/z 933.7452. 
               4″-O-Hexadecyl kanamycin (K416).1H NMR (300 MHz, METHANOL-






2.4 (m, 1H), 2.0 – 1.9 (m, 1H), 1.5 – 1.4 (m, 2H), 1.3 – 1.1 (m, 26H), 0.86 (t, J = 
7.2 Hz, 3H); 13C NMR (100 MHz, METHANOL-D4) δ 100.2, 94.6, 85.2, 79.6, 
74.8, 73.4, 73.0, 72.9(2C), 71.9, 71.8(2C), 69.1, 69.0, 60.5, 54.8, 50.3, 40.9, 
31.8, 29.9, 29.6(10C), 29.3, 25.8, 22.5, 13.2; ESI/APCI calcd for C34H69N4O11 ([M 



















(1). Fisher,M.C.; Henk,D.A.; Briggs,C.J.; Brownstein,J.S.; Madoff,L.C.; 
McCraw,L. Emerging fungal threats to animal, plant and ecosystem health.2012, 
Nature. 484, 186–194. 
(2). Strange, R. N.; Scott, P. R. Plant disease: a threat to global food security. 
Ann. Rev. Phytopathol.2005, 43, 83–116. 
(3). Jarvis, J. N.; Harrison, T. S.Pulmonary cryptococcosis. Semin. Respir. Crit. 
Care Med. 2008, 29, 141–150. 
(4). Lee, H.B.; Kim, Y.; Kim, J.C.; Choi, G.J.; Park, S.-H.; Kim, C.-J.; Jung, H.S. 
Activity of some aminoglycoside antibiotics against true fungi, Phytophthora and 
Pythium species. J. Appl. Microbiol. 2005, 99, 836–843. 
(5). (a) Lynch, S. R.; Puglisi, J. D. Structural origins of aminoglycoside specificity 
for prokaryotic ribosomes. J. Mol. Biol.2001, 306, 1037–1058; (b) Wilhelm, J. M., 
Pettitt, S. E., Jessop, J. J. Aminoglycoside antibiotics and eukaryotic protein 
synthesis: structure—function relationships in the stimulation of misreadingwith a 
wheat embryo system. Biochem.1978, 17, 1143–1149. 
(6). Li, J.; Wang, J.; Czyryca, P. G.; Chang, H.; Orsak, T. W.; Evanson, R.; 
Chang, C.-W. T. Application of glycodiversification: expedient synthesis and 
antibacterial evaluation of a library of kanamycin B analogs. Org. Lett. 2004, 6, 
1381-1384. 
(7). Shrestha, S.; Grilley, M.; Fosso, M.-Y.; Chang, C.-W. T.; Takemoto, J. Y. 
Membrane lipid-modulated mechanism of action and non-cytotoxicity of novel 






(8). Chang, C. W. T.; Takemoto, J. Y. Antifungal amphiphilic aminoglycosides. 
Med. Chem. Comm.2014, 5, 1048–1057. 
(9). Aslam, M. W.; Busscher, G. F.; Weiner, D. P.; Gelder, R. D.; Rutjes, F. P.; 
Delft, F. L. V. Fully orthogonally protected 2-deoxystreptamine from 
kanamycin. J. Org, Chem. 2008. 73(13), 5131-5134. 
(10). Bräse, S.; Klaus B.; eds. Organic Azides: Syntheses and Applications. John 

































































































































































































































































































































































































































































Department of Chemistry and Biochemistry 
Utah State University, Logan, UT 84322-0300 
Cell phone: (435) 881 8335 
E-mail: qian.zhang@aggiemail.usu.edu 
Education: 
Ph.D., Organic Chemistry, Utah State University, Logan, Utah               July 2015 
B.S., Pharmacy, Lanzhou University, P. R. China    July 2010 
Teaching Experience: 
Teaching Assistant 
Utah State University, Logan, Utah                August 2010- December 2015 
Including illustration, grading, holding office hours, and assigning final grades for 
Organic Chemistry Lab 2315and Organic Chemistry Lab 2325. 
Research Experience: 
Ph.D. Graduate Student, Advisor: Prof. Cheng-Wei Tom Chang 
Department of Chemistry and Biochemistry, Utah State University 
Logan, Utah, USA                                                      September 2010-July 2015 
278 
 
 Synthesizing fluorogenic probes for the investigation of selective biomass 
Degradation by fungi 
 Synthesizing new aminoglycosides analogs and explore the potential to 
revive traditional antibacterial kanamycin as new type of antifungal agents 
 Synthesis of bioactive 1-alkyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-diones 
and  N-aryl-2-aminomethylene1,3-indanedions using water as solvent 
 Divergent and facile Lewis Acid-mediated synthesis of N-alkyl 2-
aminomethylene-1,3-indanediones and 2-alkylamino-1,4-naphthoquinones 
Undergraduate Researcher, Advisor: Prof. Xiaodong Hu 
School of Pharmacy, Lanzhou University 
Lanzhou, Gansu, P.R. China                                                 May 2009 -July 2010 
Techniques and Expertise: 
Software: Ms Office, Windows, Chemdraw 
Languages: Madarin and English 
Research Skills: Organic Synthesis, Medicinal Chemistry, Green Chemistry 
Spectroscopy, HPLC, UV/Vis, Chromatography, Antibacterial and MIC test. 
Publications: 
1. Stereoselective Potencies and Relative Toxicities of γ-Coniceine and 
N-Methylconiine Enantiomers, Stephen T. Lee, Benedict T. Green, 
Kevin D. Welch, Glenn T. Jordan, Qian Zhang, Kip E. Panter, David 
279 
 
Hughes, Cheng-Wei Tom Chang, James A. Pfister, and Dale R. Gardner. 
Chem. Res. Toxicol. 2013, 26 (4), 616-621. 
2. Synthesis of bioactive 1-alkyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-
diones and N-aryl-2-aminomethylene-1,3-indanediones using water 
as the solvent, Qian Zhang, Jaya P. Shrestha, Cheng-Wei Tom Chang, 
Tetra. Lett.2014, 55, 1839-1842.  
3. Divergent and facile Lewis acid-mediated synthesis of N-alkyl 2-
aminomethylene-1,3-indanediones and 2-alkylamino-1,4-
naphthoquinones, Qian Zhang, Cheng-Wei Tom Chang, Tetra. 
Lett.2015, 7, 893-896. 
4. Using Fluorogenic Probes for the Investigation of Selective Biomass 
Degradation by Fungi,Qian Zhang, Xinrui Peng, Michelle Grilley, Jon 
Takemoto, Cheng-Wei Tom Chang, Green Chem. 2015, 17, 1918-1925. 
5. Structure–Activity Relationships for Antibacterial to Antifungal 
Conversion of Kanamycin to Amphiphilic Analogues. Marina Fosso, 
Madher N. AlFindee, Qian Zhang, Vincent de Paul Nzuwah Nziko, Yukie 
Kawasaki, Sanjib K. Shrestha, Jeremiah Bearss, Rylee Gregory,Jon Y. 
Takemoto, and Cheng-Wei Tom Chang,J. Org. Chem., 2015, 80 (9), 
4398–4411. 
6. Three new fusidic acid derivatives and their antibacterial activity 
Shuwei Zhang, Siyuan Wang, Qian Zhang, Cheng-Wei Tom Chang, Jixun 
Zhan. Bioorg. Med.Chem. Lett., 2015, 25(9), 1920-1924. 
280 
 
7. Converting Kanamycin A from Traditional Antibacterial Agents to 
Antifungal Cationic Amphiphiles though Surprising Site-Selective 
Alkylation of Kanamycin Hydroxyls, Qian Zhang, Madher Alfindee, 
Xinrui Peng, Jon Y. Takemoto, and Cheng-Wei Tom Chang, (Manuscript 
in preparation). 
Conference and Seminar: 
1. Poster presentation: “Synthesis of fluorogenic probes for selective 
biomass degradation by fungi” 249th ACS National Meeting & Exposition, 
Denver, CO, March, 2015,United States. 
2. SBI Science & Technology Review Winter Meeting, February 5th, 2015, 
Logan, Utah.  
3. ACS 248th National Meeting, August,2014, San Francisco, USA; 
4. SBI Science & Technology Review Winter Meeting, February 12th, 2014, 
Logan, Utah.  
5. Graduate Student Grant Writing Seminar:  “Getting Started as a 
Successful Proposal Writer and Academician seminar” February 26th, 
2013, Utah. 








Poster and Oral Presentation: 
1. “Synthesis of fluorogenic probes for selective biomass degradation by 
fungi” ACS 2015, 249th National Meeting, 2015, Denver. 
2. “Synthesis of Carbohydrate Esters as Green Antibacterial/Antifungal 
Agents” SBI 2015 Annual Meeting, Logan, Utah State University. 
3. “On water synthesis of bioactive 1-alkyl-1H-naphtho[2,3-d][1,2,3]triazole-
4,9-diones and N-aryl-2-aminomethylene-1,3-indanediones” ACS 2014, 
248th National Meeting, 2014, San Francisco. 
4. Oral presentation, April 10th, 2014, Utah State University Graduate 
Student Research Symposium.  
Honor and Award:  
• 2015, PhD Completion Award, Utah State University. 
• 2009 Chun-Tsung Scholar for outstanding undergraduate researcher, 
Lanzhou University. 
• 2009, Third Class Scholarship in Lanzhou University. 
• 2008, Second Class Scholarship in Lanzhou University. 
• 2007, Second Class Scholarship in Lanzhou University. 
• 2007, National Scholarship for Encouragement, Ministry of Education of 







Dr. Cheng-Wei Tom Chang, 
Professor 
Department of Chemistry and 
Biochemistry 
Utah State University 
0300 Old Main Hill 




Dr. Alvan C. Hengge, Professor 
Department of Chemistry and 
Biochemistry 
Utah State University 
0300 Old Main Hill 




Dr. Lisa M. Berreau, Professor 
Department of Chemistry and 
Biochemistry 
Utah State University 
0300 Old Main Hill 




Dr. Bradley S. Davidson, Professor 
Department of Chemistry and 
Biochemistry 
Utah State University 
0300 Old Main Hill 




Dr. Jon Y. Takemoto, Professor 
Department of Biology 
Utah State University 
5305 Old Main Hill 
Logan, Utah, 84322-5305 
435-797 0671 
jon.takemoto@usu.edu
